1 Multi-omic association study identifies DNA methylation-mediated genotype and smoking

2 exposure effects on lung function in children living in urban settings

- 3
- 4 Matthew Dapas¹, Emma E. Thompson¹, William Wentworth-Sheilds¹, Selene Clay¹, Cynthia M. Visness²,
- 5 Agustin Calatroni², Joanne E Sordillo³, Diane R. Gold^{4,5}, Robert A. Wood⁶, Melanie Makhija⁷, Gurjit K.
- 6 Khurana Hershey^{8,9}, Michael G. Sherenian^{8,9}, Rebecca S. Gruchalla¹⁰, Michelle A. Gill¹¹, Andrew H.
- 7 Liu¹², Haejin Kim¹³, Meyer Kattan¹⁴, Leonard B. Bacharier¹⁵, Deepa Rastogi¹⁶, Matthew C. Altman¹⁷,
- 8 William W. Busse¹⁸, Patrice M. Becker¹⁹, Dan Nicolae²⁰, George T. O'Connor²¹, James E. Gern¹⁸, Daniel
- 9 J. Jackson¹⁸, Carole Ober¹
- 10
- 11
- 12 ¹ Department of Human Genetics, University of Chicago, Chicago IL
- 13 ² Rho Inc., Durham, NC
- 14 ³Department of Population Medicine, Harvard Medical School, Boston, MA
- ⁴ Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA
- 16 ⁵ Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
- ⁶ Department of Pediatrics, Johns Hopkins University Medical Center, Baltimore, MD
- 18 ⁷ Division of Allergy and Immunology, Ann & Robert H. Lurie Children's Hospital, Chicago, IL
- 19 ⁸ Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH
- 20 ⁹ Division of Asthma Research, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
- 21 ¹⁰ Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
- 22 ¹¹ Department of Pediatrics, Washington University School of Medicine, St. Louis, MO
- 23 ¹² Department of Allergy and Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora,
- 24 со
- 25 ¹³ Department of Medicine, Henry Ford Health System, Detroit, MI
- 26 ¹⁴Columbia University College of Physicians and Surgeons, New York, NY
- ¹⁵ Monroe Carell Jr. Children's Hospital at Vanderbilt University Medical Center, Nashville, TN
- 28 ¹⁶Children's National Health System, Washington, DC
- 29 ¹⁷ Department of Allergy and Infectious Diseases, University of Washington, Seattle, WA
- 30 ¹⁸ Department of Pediatrics and Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
- 31 ¹⁹National Institute of Allergy and Infectious Diseases, Bethesda, MD
- 32 ²⁰ Department of Statistics, University of Chicago, Chicago, IL
- 33 ²¹ Pulmonary Center, Boston University School of Medicine, Boston, MA

34 ABSTRACT

35 Impaired lung function in early life is associated with the subsequent development of chronic respiratory 36 disease. Most genetic associations with lung function have been identified in adults of European descent 37 and therefore may not represent those most relevant to pediatric populations and populations of different 38 ancestries. In this study, we performed genome-wide association analyses of lung function in a 39 multiethnic cohort of children (n=1035) living in low-income urban neighborhoods. We identified one 40 novel locus at the TDRD9 gene in chromosome 14q32.33 associated with percent predicted forced expiratory volume in one second (FEV₁) (p= 2.4×10^{-9} ; $\beta_z = -0.31$, 95% CI= -0.41- -0.21). Mendelian 41 42 randomization and mediation analyses revealed that this genetic effect on FEV_1 was partially mediated by 43 DNA methylation levels at this locus in airway epithelial cells, which were also associated with 44 environmental tobacco smoke exposure (p=0.015). Promoter-enhancer interactions in airway epithelial 45 cells revealed chromatin interaction loops between FEV₁-associated variants in TDRD9 and the promoter 46 region of the *PPP1R13B* gene, a stimulator of p53-mediated apoptosis. Expression of *PPP1R13B* in airway epithelial cells was significantly associated the FEV₁ risk alleles ($p=1.26 \times 10^{-5}$; $\beta=0.12, 95\%$ 47 CI=0.06-017). These combined results highlight a potential novel mechanism for reduced lung function 48 49 in urban youth resulting from both genetics and smoking exposure.

50 AUTHOR SUMMARY

51 Lung function is determined by both genetic and environmental factors. Impairment of lung function can 52 result from harmful environmental exposures in early life, which disproportionally affect children living 53 in low-income, urban communities. However, most genetic association studies of lung function have been 54 performed in adults and without regard for socioeconomic status. Therefore, genetic risk factors 55 discovered to date may not reflect those most relevant to high-risk populations. In this study, we sought to 56 identify genetic variants correlated with lung function in a multiethnic cohort of children living in low-57 income, urban neighborhoods and analyze how tobacco smoke exposure may influence any genetic 58 effects. We discovered a common genetic variant associated with lower lung function in this population, 59 and we found that the association was mediated by nearby epigenetic changes in DNA methylation, which 60 were in turn correlated with smoking exposure. We then identified a nearby gene, *PPP1R13B*, which is 61 known to aid in the deactivation of damaged cells, whose expression in airway cells aligned with these 62 genetic and epigenetic effects. This study reveals a potential mechanism through which genetic risk and 63 environmental exposures can affect airway development, perhaps leading to interventions that can help 64 reduce the burden of asthma in socioeconomically disadvantaged children.

65 INTRODUCTION

Reduced lung function is a hallmark of asthma and chronic obstructive pulmonary disease (COPD). Lung
function measures, such as forced expiratory volume in one second (FEV₁) and forced vital capacity
(FVC), are strong predictors of future all-cause mortality [1-6]. Airway obstruction often begins in early
life [7-10], with lower lung function in infancy being a risk factor for the development of asthma in
childhood [11] and COPD in late adulthood [12].

71 Genetic factors contribute to differences in lung function among individuals, with heritability 72 estimates ranging from 0.50 for FEV₁ to 0.66 for FEV₁/FVC ratio [13]. The many genome-wide 73 association studies (GWAS) of lung function measures [14-25] have implicated pathways related to lung 74 development [20,26-28], inflammation [26], and tissue repair [29], among others [29]. Lung function is 75 also affected by environmental exposures, such as smoking [30-32] and air pollution [33], which can 76 disrupt airway development in early life, increasing the risk of childhood asthma and perhaps other 77 chronic obstructive diseases [8-12,34,35]. For example, exposure to second hand smoke in utero and 78 through childhood is associated with increased risk of childhood asthma [36], lower lung function in 79 adolescence [37], and larger declines in lung function later in life [38,39]. Such adverse exposures are 80 known to alter the epigenetic landscape in exposed individuals [40,41], potentially mediating downstream 81 biological effects [42-44] and modifying genetic associations with lung function [45,46].

82 Environmental risk factors disproportionally affect socioeconomically disadvantaged children, 83 particularly those living in urban environments [47,48]. In fact, socioeconomic effects contribute to 84 disparities in lung health [49], including the higher burden of chronic respiratory disease among Black 85 and Hispanic children compared to non-Hispanic white children [49-52]. Most genetic association studies 86 of lung function, however, have been limited to adults of European descent. Therefore, genetic risk 87 factors discovered to date may not reflect those most relevant to high-risk populations, which can further 88 exacerbate health disparities [53,54]. Identifying genetic variants and epigenetic variation associated with 89 lung function in high-risk, multiethnic, pediatric populations may provide more direct insights into the 90 early development of impaired lung function.

91	In this study, we analyzed measures of lung function from the Asthma Phenotypes in the Inner
92	City (APIC) [55,56] and Urban Environment and Childhood Asthma (URECA) cohorts [57], which
93	consist of children living in low-income neighborhoods in 10 U.S. cities. We performed whole-genome
94	sequencing (WGS) on 1,035 participants from APIC and URECA (ages 5-17 years; 67% non-Hispanic
95	Black, 25% Hispanic; 66% with doctor-diagnosed asthma) and performed a GWAS with FEV_1 and the
96	FEV ₁ /FVC ratio. We then performed expression quantitative trait locus (eQTL) and methylation
97	quantitative trait locus (meQTL) mapping in airway epithelial cells and peripheral blood mononuclear
98	cells (PBMCs) from a subset of the URECA children. We further tested for genotype and DNA
99	methylation interactions with smoking exposure. We aimed to identify methylation-mediated genetic and
100	smoking exposure associations with lung function, linking environmental effects, epigenetic
101	modifications, and specific genetic risk alleles to reduced pulmonary health in urban youth.
102	
103	
104	RESULTS
105	Genetic variants at the TDRD9 locus are associated with lung function
106	We completed WGS and variant calling on 1,035 participants from the APIC and URECA studies
107	(APIC=508, URECA=527; Table 1). The mean sequencing depth was 31.6x per sample (S1A Fig). On
108	average, 95.3%, 90.3% and 62.6% of each genome was mapped with at least 10x, 20x and 30x
109	sequencing read depth, respectively (S1B Fig). Approximately 3.8 million high-confidence autosomal
110	variants were called per sample. Variant call concordance between replicate sample pairs (n=3) was
111	>99.9% for single nucleotide polymorphisms (SNPs) and was 98.9% for insertions and deletions (S1
112	Table).

Characteristic	All	APIC	URECA
Number	1035	508	527
Age, years, mean (SD)	10.3 (2.5)	10.9 (3.1)	9.6 (1.1)
Female sex	477 (46%)	216 (43%)	261 (50%)
Race/Ethnicity			
Black (non-Hispanic)	696 (67%)	319 (63%)	377 (72%)
White (non-Hispanic)	14 (1%)	7 (1%)	7 (1%)
Hispanic	258 (25%)	153 (30%)	105 (20%)
Other/mixed	64 (6%)	26 (5%)	38 (7%)
Unknown	3 (<1%)	2 (<1%)	1 (<1%)
Site			
Baltimore	234 (23%)	85 (17%)	149 (28%)
Boston	189 (18%)	65 (13%)	124 (23%)
Chicago	62 (6%)	62 (12%)	-
Cincinnati	45 (4%)	45 (9%)	-
Dallas	38 (4%)	38 (9%)	-
Denver	59 (6%)	59 (12%)	-
Detroit	50 (5%)	50 (10%)	-
New York	164 (16%)	64 (13%)	100 (19%)
St. Louis	155 (15%)	-	155 (29%)
Washington, D.C.	39 (4%)	39 (8%)	-
Household income < \$15k	550 (54%)	273 (54%)	277 (54%)
Caretaker completed HS	756 (73%)	364 (72%)	392 (74%)
Caretaker smokes*	315 (33%)	123 (27%)	192 (39%)
Asthma	681 (75%)	508 (100%)	173 (43%)
BMI, Z-score, mean (SD)	0.9 (1.2)	1.0 (1.2)	0.8 (1.1)
FEV_1 , % predicted, mean (SD)	94.9 (16.3)	91.9 (17.6)	98.5 (14.5)
FEV/FVC, mean (SD)	0.80 (0.09)	0.78 (0.10)	0.83 (0.07)

113 Table 1. Demographic characteristics of sequenced APIC and URECA participants.

Results are presented as counts and percentages or as means with standard deviations. Missing data were not included in percentage calculations. Ages for URECA correspond to the year the genome-wide association study lung function data were collected. *Caretaker smoking status in URECA was collected at age 10. APIC: Asthma Phenotypes in the Inner City; BMI: body mass index; FEV₁: forced expiratory volume in one second; FEV₁/FVC: ratio of FEV₁ to forced vital capacity; HS: high school; URECA: Urban Environment and Childhood Asthma.

121 The sequenced cohort included 696 (67%) participants who self-identified as non-Hispanic Black

122 and 258 (25%) who self-identified as Hispanic (Table 1). Principal component and admixture analyses

123 using genotypes were used to characterize the ancestry of the participants (Fig 1). This revealed that the

¹²⁰

124 genetic ancestry of our sample was 66% African, 26% European, 7% Native American, and 1% East

125 Asian. The cohort was 54% male and included 681 (66%) children diagnosed with asthma (**Table 1**).

126

127 Fig 1. Ancestry composition of sequenced APIC & URECA participants. A) The top two principal 128 components (PCs) of ancestry are plotted for sequenced APIC & URECA participants, colored by self-129 identified race/ethnicity, along with the four ancestral reference populations used for determining 130 ancestry. NS= not specified. B) The proportion of genetic variance explained by each of the top 10 PCs. 131 C) The relative values of the top 10 PCs are plotted for each sample, colored by reference population. D) 132 The estimated proportion of admixture from each ancestral population is shown for each sequenced APIC 133 & URECA participant. Each vertical line corresponds to one sample. 1KG, 1000 Genomes project; HGDP, 134 Human Genome Diversity Project; YRI, Yoruba in Ibadan, Nigeria; CEU, Utah residents with Northern and 135 Western European ancestry; CHB, Han Chinese in Beijing, China; JPT, Japanese in Tokyo, Japan; NAT, 136 Native Americans from HGDP; EAS, East Asian ancestry; AFR, African ancestry; EUR, European 137 ancestry.

138

Using the WGS variant calls for 14.1 million variants with minor allele frequency (MAF) ≥ 0.01 ,

140 we performed a GWAS of two lung function traits: FEV₁ (% predicted) and FEV₁/FVC (Z-scores),

141 measured between ages 5-17 (**Table 1**, **S2 Fig**), adjusting for age, sex, asthma diagnosis, the first 10

142 principal components (PCs) of ancestry, and sample relatedness using a linear mixed model [58]. The

143 FEV₁ GWAS included 896 participants from APIC (n=504) and URECA (n=392), and the FEV₁/FVC

144 GWAS included 886 participants from APIC (n=497) and URECA (n=389). The genomic control factor,

145 λ_{GC} , for both GWAS results was 1.02 (S3 Fig), indicating adequate control for population stratification.

146 We identified one locus on chromosome 14q32.33 that was associated with FEV₁ at genome-wide

147 significance ($p < 2.5 \times 10^{-8}$); no other variants were associated with FEV₁ and no variants were associated

148 with FEV_1/FVC at genome-wide levels of significance (**Fig 2**). The FEV_1 locus on chromosome 14

149 consisted of a 200 kb region of associated variants in high linkage disequilibrium (LD) across the TDRD9

150 (Tudor Domain Containing 9) gene (Fig 3, S2 Table). The minor allele at the lead SNP (rs10220464;

- 151 MAF=0.30) was significantly associated with lower FEV₁ (p= 2.4×10^{-9} ; $\beta_z = -0.31$, 95% confidence
- 152 interval (CI)= -0.41- -0.21) and nominally associated with lower FEV₁/FVC (p=1.1x10⁻³; β_z = -0.17, 95%

153 CI= -0.28- -0.07). Fine-mapping analysis at this locus (chr14:103.7-104.3Mb) revealed one 95% credible

set of effect variables consisting of 59 SNPs, with rs10220464 having the highest individual posterior

- 155 inclusion probability among them (S4 Fig). We did not detect any significant differences in rs10220464
- association effect size by ancestry or asthma status or study for FEV_1 (Fig 4). Furthermore, the *TDRD9*
- 157 locus remained the only genome-wide significant association when the two GWAS were performed
- 158 without adjustment for asthma status (S5 Fig). The overall effect size correlations between asthma-
- 159 adjusted and unadjusted GWAS results were r=0.981 for FEV₁ and r=0.954 for FEV₁/FVC.
- 160

Fig 2. Genome-wide association results. GWAS Manhattan plots for **A**) FEV₁ and **B**) FEV₁/FVC ratio. The horizontal red line indicates genome-wide significance ($p \le 2.5 \times 10^{-8}$). The dotted horizontal blue line indicates $p=1 \times 10^{-5}$. Variants colored in green are in previously identified GWAS loci [23]. FEV₁, forced expiratory volume in one second; FEV₁/FVC, ratio of FEV₁ to forced vital capacity.

165 166

167 Fig 3. FEV₁-associated variants on chromosome 14q32.33. FEV₁ association results are shown at the TDRD9 gene locus. Each variant is plotted according to its position and -log₁₀ p-value, colored by linkage 168 169 disequilibrium to the lead variant, rs10220464, within the sample. Candidate cis-Regulatory Elements 170 (cCREs) from ENCODE [59] are also shown for the region. The inset panel in the upper right shows the 171 distribution of adjusted FEV₁ values by rs10220464 genotype. FEV₁, forced expiratory volume in one 172 second; MAF, minor allele frequency; EnhD, distal enhancer-like signature; CTCF, CCCTC-binding factor 173 sites; enhP, proximal enhancer-like signature; prom, promoter-like signature; K4m3, trimethylation of 174 histone H3 at lysine 4.

175 176

177Fig 4. Rs10220464 effect size heterogeneity. A forest plot of the associations between rs10220464 and178FEV1 (% predicted) are shown for distinct sub-cohorts distinguished by self-identified race/ethnicity, study,179and asthma status. β_z , the association effect size between the rs10220464 allele count and the adjusted180and normalized FEV1 (% predicted) values. FEV1, forced expiratory volume in one second; N, total181number of individuals included in the association test; MAF, minor allele frequency within the sub-cohort;182P, the association p-value.

183

184	We examined association results for the previously identified FEV_1 and FEV_1/FVC loci reported
185	in the meta-analysis of the UK Biobank and SpiroMeta Consortium by Shrine and colleagues (n=400,102)
186	[23], which included 70 loci for FEV ₁ and 117 for FEV ₁ /FVC. Of these, 64 of the lead SNPs for FEV ₁
187	and 112 for FEV_1/FVC were genotyped in the APIC and URECA sample. Only one SNP, for FEV_1 ,
188	replicated with false discovery rate (FDR) q<0.05 (rs9610955; p=1.0x10 ⁻⁴ ; β_z = -0.38, 95% CI= -0.58
189	0.19; S6 Fig, S7 Fig). Cumulatively, 56% (n=36) and 54% (n=60) of these SNPs demonstrated consistent
190	directions of effect for FEV ₁ and FEV ₁ /FVC, respectively, with effect size correlations of 0.29 (95% CI=

191 0.05- 0.50; p=0.020) for FEV₁ and 0.42 (95% CI=0.25- 0.56; p= 4.2×10^{-6}) for FEV₁/FVC.

192

Lung function risk alleles are associated with DNA methylation at the TDRD9 locus in airway 193 194 epithelial cells 195 The majority of complex trait-associated variants exert effects by altering gene regulatory networks [60-196 62]. These changes are often marked by quantitative differences in DNA methylation levels [63-65]. We 197 therefore investigated correlations between the FEV₁-associated allele at TDRD9 and DNA methylation at 198 the locus in upper airway (nasal) epithelial cells (NECs) from URECA children at age 11 (n=286). We 199 tested for associations between the FEV₁ genotype, as tagged by rs10220464, and DNA methylation 200 levels at 796 CpG sites within 10 kb of any TDRD9 locus variants associated with FEV₁ at $p<1x10^{-5}$ 201 (n=82 variants). The rs10220464 genotype was an meQTL for 5 CpG sites at an FDR <0.05 (S3 Table). DNA methylation levels at only one of these CpG sites, cg03306306 (p=2.3 x10⁻⁴; β =0.07, 95% CI=0.03-202 203 0.10; Fig 5a), was also significantly associated with FEV₁ at age 10 in URECA (p=0.011; β = -11.48, 95% 204 CI= -20.27- -2.69; Fig 5b). The rs10220464 genotype accounted for 4.7% of residual variation in 205 cg03306306 methylation, and cg03306306 methylation explained 2.4% of residual variation in FEV₁. 206 207 Fig 5. Genotype and FEV₁ associations with DNA methylation. DNA methylation levels at 208 cq03306306 are shown by rs10220464 genotype and FEV₁ measures are plotted against cg03306306 209 methylation levels in NECs at age 11 (A, B), and PBMCs at age 7 (C, D) from URECA. FEV₁, forced 210 expiratory volume in one second; NECs, nasal epithelial cells; PBMCs, peripheral blood mononuclear 211 cells; URECA, Urban Environment and Childhood Asthma study. 212 213 We then analyzed cg03306306 methylation in PBMCs collected at age 7 (n=169) [66] from 214 URECA children to evaluate whether the genotype and lung function associations observed in NECs were 215 shared with blood cells. In PBMCs, we observed no correlation between the rs10220464 risk allele and 216 cg03306306 methylation (Fig 5c), nor was there an association between cg03306306 methylation and 217 FEV_1 (Fig 5d). These results indicate that cg03306306 methylation dynamics in the airway epithelium are 218 not present in peripheral blood cells. 219

220	Smoking exposure is associated with DNA methylation at the TDRD9 locus
221	DNA methylation at the TDRD9 locus had previously been associated with maternal smoking during
222	pregnancy [67,68]. Therefore, we tested for associations between environmental tobacco smoke exposure
223	(S8 Fig) and DNA methylation at this locus in the URECA children. Methylation at cg03306306 in NECs
224	was significantly associated with nicotine metabolite (cotinine) levels in urine collected at ages 7-10 years
225	(p=0.015; β =0.03, 95% CI=0.01-0.05; Fig 6). Methylation at cg03306306 in PBMCs from age 7 was not
226	associated with urine cotinine levels.
227 228 229 230 231	Fig 6. DNA methylation association with smoking exposure. DNA methylation at cg03306306 in nasal epithelial cells at age 11 are plotted against urine cotinine levels from URECA at ages 8-10 as measured using the NicAlert assay (n=285). URECA, Urban Environment and Childhood Asthma study.
232	To determine if there was an interaction effect between genotype and smoking exposure on DNA
233	methylation and/or lung function, we repeated the cotinine association tests in URECA with the addition
234	of an interaction term to assess if the genotype effect differed between individuals with low and high
235	exposures to smoking. There were no significant genotype-by-smoking exposure interaction effects on
236	methylation levels in NECs or PBMCs in URECA, nor were there any significant methylation-by-
237	smoking effects on FEV_1 (S9 Fig). There was modest evidence for a genotype-by-smoking exposure
238	interaction effect on FEV_1 in the combined APIC and URECA sample, but this did not reach statistical
239	significance (p=0.06, S10 Fig). Considering the ages of the participants in APIC and URECA, most
240	tobacco exposures were likely due to secondhand smoke.
241	
242	Genetic effects on lung function are mediated by DNA methylation
243	To determine if DNA methylation at the <i>TDRD9</i> locus had a causal effect on lung function, we performed
244	a Mendelian randomization analysis using two-stage least squares (2SLS) regression. In the first stage,
245	cg03306306 methylation levels in NECs were regressed on an instrument composed of four meQTLs for
246	cg03306306 (rs11160777, rs137961671, rs7143936, rs11160776; Materials and Methods). In the
247	second stage, FEV_1 was regressed on the predicted DNA methylation values generated from the first stage

248 regression, thereby yielding a causal effect estimate of cg03306306 methylation on FEV₁. Urine cotinine 249 levels were included as a covariate in both stages. The variance explained in the first stage regression was 250 $r^2=0.11$. The causal effect of cg03306306 methylation on FEV₁ was statistically significant (p=0.020). We 251 also tested a single, unweighted allele score of the instrumental variables and observed a causal effect 252 association of p=0.045 (stage-one r^2 =0.10). We further performed a bootstrapped mediation analysis to 253 test whether the rs10220464 risk allele effect on FEV_1 was mediated by DNA methylation. The indirect 254 effect of rs10220464 on FEV₁ via cg03306306 methylation was significant, both when including asthma 255 as a covariate (β_z =-0.04, 95% CI=-0.10- -0.003, percent mediated=14.4%) and when asthma was not 256 considered (β_{z} =-0.04, 95% CI=-0.10- -0.002, percent mediated=15.0%). These results indicate that the 257 effect of the FEV_1 -associated genotype at the *TDRD9* locus is partially mediated through its impact on 258 nearby DNA methylation levels. 259 260 Gene expression and promoter-enhancer interactions implicate PPP1R13B 261 Trait-associated variants and DNA methylation often affect the transcriptome by influencing the 262 expression of one or more neighboring genes [69,70]. Identifying these correlations can help infer causal 263 mechanisms [71]. Therefore, we next explored the relationship between the genotype for the lead FEV_1 264 variant rs10220464 and the expression of genes within 1 Mb in NECs and PBMCs from URECA 265 children. Notably, the rs10220464 genotype was not associated with TDRD9 expression levels in these 266 cells (NECs: p=0.60, β = 0.116; PBMCs: p=0.91, β = 0.014). Of the 27 genes that were evaluated (S4 267 Table), rs10220464 was significantly associated with the expression of only one gene, PPP1R13B 268 (Protein Phosphatase 1 Regulatory Subunit 13B; FDR $q=2.77.x10^{-4}$; $p=1.26x10^{-5}$; $\beta=0.12$, 95% CI=0.06-269 017; Fig 7a), in NECs. *PPP1R13B* expression levels were also the most strongly associated of the 27 270 genes with methylation at cg03306306 in NECs (p=0.018; β =0.10, 95% CI=0.02-018; Fig 7b). 271 *PPP1R13B* expression in NECs, however, was not associated with FEV_1 or smoking exposure (S11 Fig). 272

Fig 7. *PPP1R13B* gene expression in NECs. *PPP1R13B* gene expression in NECs at age 11 are plotted against A) rs10220464 genotype (n=324) and B) DNA methylation at cg03306306 in NECs at age 11 (n=254). NECs, nasal epithelial cells; CPM, counts per million.

- 276
- 277 The transcription start site of *PPP1R13B* resides 87 kb from rs10220464 and 152 kb from
- 278 cg03306306, suggesting long-range interactions between the FEV₁-associated genotype and the promoter
- of *PPP1R13B*. To determine whether any of the FEV₁-associated GWAS variants at the *TDRD9* locus
- 280 resided in regions that physically interacted with the promoters of *cis*-genes, we evaluated chromatin
- interactions in lower airway (bronchial) epithelial cells (BECs) [72], assessed by promoter-capture Hi-C.
- Forty-two of the GWAS variants resided in regions that interacted with the promoters of 9 different genes
- 283 expressed in NECs (Fig 8; S5 Table). The gene most frequently mapped to these variants was
- 284 *PPP1R13B*, with 15 variants located in 3 different interaction loops. Moreover, the strongest observed
- interaction was between a region containing 4 FEV₁-associated variants and the *PPP1R13B* promoter
- 286 (CHiCAGO score = 9.38; **S5 Table**), suggesting that this region is an enhancer for *PPP1R13B*
- expression. This putative enhancer region is located just 2.21 kb from cg03306306.
- 288

289 Fig 8. Promoter-enhancer interactions at TDRD9 locus in nasal epithelial cells. Promoter-to-290 enhancer chromatin interactions captured by Hi-C in nasal epithelial cells from URECA at age 11 are 291 displayed as grey arcs. SNPs associated with FEV_1 (p<1x10⁻⁵) are marked by blue lines in the top row 292 according to their genomic position on chromosome 14. The lead FEV₁ SNP, rs1022464, is highlighted in 293 vellow. CpG sites associated with rs1022464 (FDR<0.05) are displayed as green markers below the 294 genes, with cg03306306 highlighted in green. Chromatin Interactions containing SNPs associated with 295 FEV₁ (p<1x10⁻⁵) are highlighted in blue. Magenta arcs highlight interactions between the PPP1R13B 296 promoter and regions containing FEV₁ SNPs and/or rs1022464-associated CpG sites. FEV₁, forced 297 expiratory volume in one second; SNPs, single nucleotide polymorphisms; meQTL, methylation 298 quantitative trait locus; pcHi-C, promoter capture Hi-C.

- 299
- 300
- 301 Summary of study associations
- 302 The associations between the *TDRD9* risk allele, cg03306306 DNA methylation in NECs, smoking
- 303 exposure, *PPP1R13B* gene expression, and FEV₁ (% predicted) reported in this study are summarized in
- 304 **Fig 9**.

305

Fig 9. Summary of study associations. The *TDRD9* locus was significantly associated with FEV₁ (% predicted) in the APIC and URECA cohorts. This association was partially mediated by DNA methylation at the cg03306306 CpG site in *TDRD9* in NECs, which was also significantly associated with environmental tobacco smoke exposure. The TDRD9 risk allele and DNA methylation were both significantly associated with *PPP1R13B* gene expression, but *PPP1R13B* gene expression was not significantly correlated with FEV₁ itself. Unidirectional arrows represent inferred causality.

- 312
- 314

315 **DISCUSSION**

316 Using whole-genome sequence variant calls in an asthma-enriched cohort of predominantly African-

317 American children raised in urban environments, we identified a genotype at the TDRD9 locus associated

318 with lower FEV₁ % predicted. This genotype effect was partially mediated by DNA methylation in airway

319 epithelial cells, which were also correlated with smoking exposure. Data from RNA-sequencing and

320 promoter-capture Hi-C in airway epithelial cells suggested that these FEV₁-associated genetic and

321 epigenetic variations influence the expression of the *PPP1R13B* gene through long-range interactions.

322 The *PPP1R13B* gene encodes a protein that promotes apoptosis, a form of programmed cell

death, via its interaction with the tumor suppressor p53 and is often referred to by its alias ASPP1

324 (apoptosis-stimulating protein of p53 1) [73]. In response to oncogenic stress, PPP1R13B translocates to

325 the nucleus, where it enhances the transcriptional activity of p53 on specific target genes relevant to

326 apoptosis [74,75]. Exposure to smoking and fine particulate matter induces epithelial apoptosis in the

327 lung via p53 [76-78]. PPP1R13B may also promote apoptosis in a p53-independent manner by inhibiting

328 autophagy in response to upregulation by EGR-1 (early growth response protein 1) [79]. EGR-1 mediates

329 stress-induced proinflammatory responses in the airway epithelium and contributes to the pathogenesis of

330 COPD [80-85]. Within the lung, *PPP1R13B* is indeed predominantly expressed in epithelial cells,

particularly in alveolar type 2 cells, and less so in immune cells and fibroblasts [86,87]. However, Cheng

and colleagues studied PPP1R13B function in lung fibroblasts and found that it was upregulated

following SiO₂ exposure, where it promoted fibroblast proliferation and migration through endoplasmic

reticulum stress and autophagy pathways [88]. Overall, these studies suggest that *PPP1R13B* plays a key

335 role in maintaining tissue homeostasis by regulating apoptosis and autophagy in response to 336 environmental stimuli [74,89,90]. The specific function(s) of this gene in the airway epithelium and its 337 potential impact on the development of airway obstruction remain to be elucidated. PPP1R13B 338 expression in airway epithelial cells at age 11 was not directly associated with lung function or urine 339 cotinine levels in the URECA children, but the cofactors of this gene [79,91] have been found previously 340 to be upregulated in smokers with COPD [81,92]. Given its association with lung function alleles in our 341 study, its expression in the airway epithelium, and its purported functions in autophagy and apoptosis 342 pathways, additional study of *PPP1R13B* in lung and airway development is warranted, particularly in the 343 context of adverse environmental stimuli, many of which are enriched in low-income urban 344 environments. 345 In NECs, *PPP1R13B* gene expression was significantly associated with DNA methylation levels 346 at the cg03306306 CpG site in TDRD9. Methylation at the TDRD9 locus was previously reported to 347 correlate with specific environmental exposures [67,68,93] and with TDRD9 expression in blood [67,94]. 348 TDRD9 is lowly expressed in the lung but is detected in alveolar macrophages and in monocytes [86,87]. 349 Interestingly, the gene was among the most differentially expressed genes in alveolar macrophages in 350 smokers relative to non-smokers [95], and its knockdown in TDRD9-expressing lung carcinomas resulted 351 in increased apoptosis [96]. Its expression was not correlated with the rs10220464 genotype in URECA 352 NECs or PBMCs, but rs10220464 is an eQTL for TDRD9 expression in whole blood in GTEx data [97], 353 with the minor allele associated with lower TDRD9 expression. Although evidence from this study points 354 to *PPP1R13B* in the airway epithelium, we can't exclude the possibility that *TDRD9* or other genes could 355 contribute to the locus' influence on lung function via other tissues. 356 The correlations of FEV₁ and rs10220464 with cg03306306 methylation and PPP1R13B 357 expression in NECs were absent in PBMCs. Although global DNA methylation patterns between tissues 358 are highly correlated [98], tissue-specific differentially methylated regions are more likely to be 359 functional, particularly if they are positively correlated with gene expression [99]. The TDRD9 locus has 360 not been identified in epigenome-wide association studies of lung function [44,100-104], but these

361 measured DNA methylation from blood, which may be an insufficient proxy for methylation in the lungs 362 [105]. Indeed, previous studies have found that DNA methylation profiles in NECs are significantly more 363 predictive of pediatric asthma than those in PBMCs [106,107]. Furthermore, epigenetic biomarkers can 364 change with age. For example, epigenetic markers for lung function in adults do not replicate in children 365 [101].

The FEV₁ association signal at the *TDRD9* locus included many variants in high LD across a 200 kb region that could be independently contributing to function. Some of the variants lie in different longrange enhancers [59]. It is also possible that one or more correlated variants were not included because they failed quality control standards. In addition, due to the limited sample size of the WGS cohort, we excluded rare variants (MAF<0.01) from consideration, which could contribute to the signal at this locus.

371 Additional functional studies are needed to identify the causal variant(s) and full mechanism of action.

372 If increased methylation at cg03306306 leads to lower FEV₁ in response to environmental 373 stressors, one might expect to see interaction effects with smoking exposure on FEV_1 . We did not detect 374 any such interactions, although our analyses in that regard were likely underpowered given our observed 375 effects and sample sizes [36]. Furthermore, because this study was limited to children living in low-376 income urban neighborhoods, environmental risk factors are likely to be more prevalent than in the 377 general population [55-57]. Additionally, such exposures are not necessarily ubiquitous across all the 378 different neighborhoods and communities represented in this sample, and although environmental tobacco 379 smoke exposure was examined and the socioeconomic range represented in this study is relatively 380 narrow, there could be relevant environmental factors that were not considered.

381 To infer causality, Mendelian randomization and mediation analyses rely on assumptions that are 382 often difficult to empirically verify. For the Mendelian randomization analysis, we identified instrumental 383 variants associated with the intermediate cg03306306 that were not independently associated with the 384 outcome, FEV₁. However, because these variants were selected from the same dataset that the outcome 385 testing was performed in, they were susceptible to bias from winner's curse [108]. To mitigate the 386 potential impact from this effect and from weak instruments, we performed a secondary analysis in which

387 we combined the instrumental variants into a single, unweighted score. For the mediation analysis, 388 unmeasured confounding can invalidate direct and indirect effect estimates [109]. To protect against such 389 bias, we systematically tested for confounding associations with additional environmental measures 390 available in APIC and URECA (Materials and Methods). Nonetheless, there may still exist unknown 391 confounding factors that were not measured. Ultimately the results of the Mendelian randomization and 392 mediation analyses indicate that methylation at cg03306306 in NECs mediated the rs10220464 genotype 393 effect on FEV₁, but there was residual correlation between rs10220464 and FEV₁, signifying that the 394 genotype effect was only partially mediated by cg03306306.

395 Another limitation of our study was the relatively small size for a GWAS. This likely contributed 396 to the lack of statistically significant replication for previously identified lung function loci [23], 397 considering that the observed effects were correlated with results of prior GWAS. However, the APIC 398 and URECA cohorts represent understudied, high-risk, pediatric populations that likely harbor distinct 399 genetic and environmental risk factors compared to older, primarily European ancestry cohorts included 400 in previous GWAS of lung function [14-20,23]. The findings of this study have yet to be replicated in an 401 independent cohort, and should therefore be considered preliminary; however, it is possible that these 402 associations would differ in populations with dissimilar ancestry, age, exposures, and/or asthma risk. 403 There are additional caveats to consider when interpreting our findings. First, this study 404 integrated data from two cohorts with different recruitment criteria, asthma definitions, and ancestral 405 compositions. Furthermore, most of the analyses beyond the GWAS were limited to subsets of the 406 URECA participants. However, we did not observe significant genetic effect heterogeneity for 407 rs10220464 by study, asthma status, or ancestry. To control for potential population stratification, we 408 used the first ten PCs of ancestry to adjust lung function values and then included the ancestry PCs as 409 fixed effects in the GWAS models (Materials and Methods). The linear mixed models also included a 410 genetic relatedness matrix as a random effect to account for residual population structure. Because 411 children with asthma have lower lung function overall (**Table 1**) and their lung function may be more

affected by environmental exposures [110-112], we adjusted for asthma status in the GWAS, as in

412

413 previous GWAS [113-116]. The likelihood of discovering lung function variants with consistent effects in 414 asthmatics and non-asthmatics was thereby increased, although genetic determinants of lung function may 415 differ by asthma status [117]. Furthermore, adjusting for disease status could potentially introduce 416 collider bias [118]. The significant genotype effect at the *TDRD9* locus, however, remained the only 417 genome-wide-significant association when asthma was excluded as a covariate, and adjustment for 418 asthma did not substantively alter the mediation results. Second, some of the analyses used data collected 419 at different timepoints. For example, most of the urine cotinine and spirometry measures were collected at 420 age 10, but the samples used for the NEC DNA methylation and RNA-seq analyses were collected at age 421 11. Because DNA methylation and gene expression can change over time [40,119-121], their values at 422 age 11 may not be fully representative of exposures at age 10. Finally, the promoter-capture Hi-C data 423 were from lower airway (bronchial) epithelial cells, whereas the DNA methylation and RNA-seq data 424 were generated from upper airway (nasal) epithelial cells. Although there are transcriptomic differences 425 between epithelial cells from each compartment, their respective profiles are highly correlated [122-126], 426 and the use of NECs as a proxy for the lower airway epithelium has been validated for both gene 427 expression and epigenetic studies [124-127]. 428 Our study identified a novel avenue through which genetic risk and environmental exposures 429 could affect the airways of children raised in low-income urban neighborhoods. Further research into this

430 pathway may yield mechanistic insights into the early development of impaired lung function, perhaps

431 leading to interventions that can help reduce the high incidence and morbidity of chronic respiratory

432 diseases in socioeconomically disadvantaged children.

433

434 MATERIALS AND METHODS

435 **Study Population and Phenotypes**

436 We analyzed samples and phenotypes from two National Institutes of Allergy and Infectious 437 Diseases (NIAID)-funded asthma studies conducted by the Inner-City Asthma Consortium (ICAC)[128]: 438 the Asthma Phenotypes in the Inner City (APIC) study[55,56] and the Urban Environment and Childhood 439 Asthma (URECA) birth cohort study [57]. The APIC study was a 1-year, prospective, epidemiological 440 investigation of children and adolescents with asthma (ages 6-17) living in low-income areas (>20% of 441 residents below poverty level) in nine U.S. cities (Baltimore, MD; Boston, MA; Chicago, IL; Cincinnati, 442 OH; Dallas, TX; Denver, CO; Detroit, MI; New York, NY; Washington, DC). The APIC participants 443 were required to have a diagnosis of asthma by a physician and to have had at least two episodes 444 requiring bronchodilator administration within the past year [55]. The URECA study enrolled pregnant 445 women living in low-income areas of four U.S. cities (Baltimore, MD; Boston, MA; New York, NY; St. 446 Louis, MO) who reported that either or both parents of the index pregnancy had a history of asthma or 447 allergic diseases [57]. This prospective, longitudinal study followed each child through adolescence, 448 periodically collecting samples and clinical and environmental exposure data. Institutional review board 449 approval was received from all participating sites, and written informed consent was obtained from legal 450 guardians of all participating children, who also assented.

451 Lung function was assessed using spirometry. Lung function measures used in this study for 452 APIC participants were taken at the study entry visit (V0). For URECA, measurements from age 10 were 453 used when available; otherwise, the most recent measurement after age 5 was used (S6 Table). Asthma 454 status was assigned according to study-specific criteria. For APIC, asthma was defined by a doctor's 455 diagnosis of asthma and short-acting beta-agonist use in the year prior [55]. For URECA, asthma status 456 was determined either by doctor diagnosis, lung function reversibility, or symptom recurrence [129]. The 457 2012 Global Lung Initiative reference equations [130] were applied to generate percent predicted 458 estimates for FEV_1 and Z-scores for FEV_1/FVC ratio. Urine cotinine levels were measured using NicAlert 459 immunochromatographic assays, which report results on a scale of 0-6 according to different cotinine

463	samples included in each analysis varied and was limited by data availability (S7 Table, S12 Fig).
462	DNA methylation and RNA-seq data generated for other URECA studies; therefore, the number of
461	participants (n=391); otherwise, assays from age 8 (n=29) or age 7 (n=2) were used. This study utilized
460	concentration ranges [131]. For URECA, urine cotinine results were available at age 10 for most

464

465 Whole-Genome Sequencing and Data Processing

466 DNA was extracted from peripheral blood (APIC, URECA) or cord blood (URECA) and quantified using 467 an Invitrogen Oubit 3 Fluorometer. DNA quality was assessed using the Thermo Scientific NanoDrop 468 One spectrophotometer and confirmed using an Agilent TapeStation system. DNA was processed in 469 batches of 60 using the Illumina Nextera DNA Flex library prep kit with unique dual adaptors. Each set of 470 60 libraries was sequenced over two NovaSEQ S4 flowcells. Whole-genome sequencing was performed 471 by the University of Chicago Genomics Facility using the Illumina NovaSEQ6000, which generated 150 472 bp paired-end reads. Sequencing data processing followed the Broad Institute's Genome Analysis Toolkit 473 (GATK) best practices for germline short variant discovery, as implemented in the harmonized pipeline 474 used by the New York Genome Center for TOPMed [132,133]. Reads were aligned to the GRCh38 475 human reference genome (including alternate loci and decoy contigs) using BWA-MEM (Burrows-476 Wheeler Aligner; v0.7.17). Aligned reads further underwent duplicate removal (Picard MarkDuplicates; 477 v2.8.1) and base quality score recalibration (GATK BaseRecalibrator; v3.8) against known sites 478 (dbSNP138, known indels, and Mills and 1KG gold standard indels) provided in the GATK resource 479 bundle. Read alignment metrics were calculated using Picard CollectWgsMetrics (v2.8.1) for all aligned 480 reads and for aligned reads with base quality and mapping quality ≥ 20 . DNA contamination levels were 481 estimated using VerifyBamID2 (v1.0.6) [134]. Samples with estimated DNA contamination >0.05 were 482 removed from consideration. Samples with poor coverage (<50% of the genome with >20x depth) were 483 also removed from further consideration. To identify potential sample swaps, WGS samples were 484 validated using independent genotyping arrays.

485

486 QC Array for Sample Validation

487 To identify potential WGS sample swaps, we independently genotyped the APIC and URECA 488 participants using the Illumina OC Array-24 BeadChip. SNPs were tested for Hardy-Weinberg 489 Equilibrium (HWE) within each self-identified ancestry group using the chi-square test and removed if 490 they deviated from HWE (Bonferroni-adjusted p<0.05) within at least one ancestry. SNPs with call rates 491 <0.98 were also removed. Samples with total variant call rates <0.95 were not used. Array data with 492 incorrect or indeterminate sex according to X-chromosome heterozygosity rates (Plink v1.90) were also 493 not used [135]. For fourteen of the sequenced URECA samples, we used results from the Illumina 494 Infinium CoreExome+Custom array for sample validation, which were generated and controlled for 495 quality as described by McKennan and colleagues [136]. WGS and array genotypes were tested for 496 concordance using VerifyBamID (v1.1.3) [137]. WGS samples that were not validated with array data 497 were not included in genetic analyses (n=2).

498

499 Variant Calling and Quality Control

500 Variant calls were generated using GATK HaplotypeCaller (v4.1.3.0), accounting for contamination 501 estimates, for single nucleotide variants and short insertions, deletions, and substitutions. Sample 502 genotypes were joined using GATK GenomicsDBImport and GenotypeGVCFs over the genomic 503 intervals defined in the GATK WGS calling region interval list provided in the GATK resource bundle. 504 Genotypes with read depth (DP) <10 or quality scores (GQ) <20 were set as missing. Sites with ≥ 0.1 505 missingness were then removed from consideration. Variants with minor allele frequencies >0.05 were 506 tested for accordance with HWE, accounting for population structure [138]. Sites with common variants 507 that deviated from structural HWE ($P < 1 \times 10^{-6}$) were removed from consideration. Sites with quality by 508 depth ratios (OD) <4 or >34 were also removed, as we observed declines in variant transition/transversion 509 (TS/TV) ratios beyond these bounds (S13 Fig). Variant site quality was further evaluated using machine-510 learning-based Variant Quality Score Recalibration (VQSR). First, SNPs were modeled using GATK 511 VariantRecalibrator (v4.1.3.0) with Hapmap 3 and with Omni 2.5M SNP chip array as truth resources,

512	1000G as a training resource, and dbSNP138 as a known sites resource. InDels were likewise trained with
513	the Mills and 1KG gold standard indels dataset as a truth resource and dbSNP138 as a known sites
514	resource. SNPs and InDels with resultant predicted true positive probabilities below 0.997 and 0.990,
515	respectively, were removed from consideration. Variant call accuracy was assessed by comparing call
516	concordance between three replicate sequencing samples using VCFtools (v0.1.14) vcf-compare [139].
517	Variant call file manipulation was conducted using BCFtools (v1.10.2) [140].
518	
519	Ancestry Estimation
520	Ancestry principal components (PCs) were calculated on the intersect of high quality single-nucleotide
521	variants (SNVs) genotyped in the WGS data and several reference panels from the 1000 Genomes Project
522	(1KG; n=156) [141] and the Human Genome Diversity Project (HGDP; n=52) [142]. Native American
523	reference samples consisted of 52 samples from the HGDP with <5% non-native ancestry, according to
524	an analysis of roughly 2 million markers using the program ADMIXTURE (v1.3.0) [143]. These samples
525	were filtered for site quality (missingness 5%; ExcHet<60; VQSLOD≥8.3929), genotype quality
526	(GQ≥20) and depth (DP≥10), MAF >0.02, and HWE (p>0.001) [142]. European, West African, and East
527	Asian reference samples were randomly selected from CEU (n=52), YRI (n=52), JPT (n=26), and CHB
528	(n=26) samples in the phase 3 1KG reference panel [141]. The combined genotypes were pruned for
529	linkage disequilibrium (LD) \leq 0.1 within 1Mb intervals. Ancestry PCs were calculated, accounting for
530	subject relatedness, using PC-Air [144] and PC-Relate [145]. Initial kinship estimates were produced
531	using KING[146]. Kinship and PCs were iteratively estimated using PC-Relate and PC-Air, respectively,
532	until estimates for the top 5 PCs stabilized (n=3). Reference population admixture estimates were
533	estimated for each WGS sample with ADMIXTURE (v1.3.0), using the 1KG and HGDP reference
534	samples for supervised analysis [143]. Because sample relatedness can lead to biased admixture estimates
535	[144,147], admixture was estimated for each WGS sample separately.

536

537 Quantitative Trait Association Testing

538 Quantitative traits were adjusted for covariates and normalized using a two-stage approach [148,149]. 539 First, each trait was regressed on age, sex, asthma status, and the first 10 PCs of ancestry. The residuals 540 were then rank-normalized using an inverse normal transformation. In the second stage, the normalized 541 residuals were considered outcome variables in the GWAS, adjusting for the same covariates as in the 542 first stage. Genome-wide association testing was performed for all high-quality common variant calls 543 (MAF ≥ 0.01) using a linear mixed model, as implemented in GEMMA [58], with subject relatedness 544 included as a random effect. Individuals who were not evaluated for asthma at ages 7 or 10 (n=127) were 545 excluded from trait association testing. The threshold we applied for genome-wide significance was $P \le 2.5 \times 10^{-8}$, based on a 5×10^{-8} GWAS threshold and further accounting for two tests. To identify potential 546 547 collider bias introduced by adjusting for asthma status, we repeated the GWAS without accounting for 548 asthma status in either covariate-adjustment stage.

549 Fine-mapping analysis was conducted using SuSiE (SusieR R package v0.12.27) [150]. SuSiE 550 applies a form of Bayesian variable selection in regression using iterative Bayesian stepwise selection to 551 identify "credible sets" of variables. Each credible set has a 95% probability of containing at least one 552 causal effect SNP. Prior to running SuSiE, we regressed asthma, age, sex, and ancestry PCs 1-10 from the 553 genotype matrix and outcome vector (the normalized FEV₁ residuals).

554 To explore whether there was lead-SNP effect heterogeneity by ancestry, study, or asthma status, 555 we performed additional single-SNP quantitative trait association tests within several different sub-556 cohorts and introduced interaction effects into our models. For ancestry, we performed separate 557 association tests in each of the Black, Hispanic, and white populations, according to self-identified 558 race/ethnicity. We then tested for genotype-by-ancestry interaction effects across APIC and URECA by 559 using admixture proportions as covariates in our models, in lieu of ancestry PCs, and including an 560 interaction term with the lead SNP for each continental ancestry group in turn. We tested these interaction 561 effects using the --gxe argument in GEMMA in four separate models (one for each ancestry). To 562 determine whether there was effect heterogeneity by study (APIC vs. URECA), we performed separate 563 association tests in each study and also tested the association across APIC and URECA with the addition

of a study covariate and a genotype-by-study interaction term. For asthma status, we performed separate association tests in the asthmatics and non-asthmatics and tested a genotype interaction term with asthma status.

567

568 **DNA Methylation Analysis**

569 DNA from NECs was collected at age 11 from 287 URECA participants and assessed for genome-wide

570 methylation patterns using the Illumina Infinium Human Methylation EPIC Beadchip. DNA methylation

571 levels from PBMCs at age 7 in URECA were collected and processed as previously described [66].

572 MeQTL analysis was performed using Matrix eQTL [151]. NEC DNA methylation levels were adjusted

573 globally for sex, array, plate, collection site, DNA concentration, percent ciliated epithelial cells, percent

574 squamous cells, and ancestry PCs 1-3. Principal components analysis was then performed on the residual

575 methylation levels, and the first three PCs were included as covariates in the meQTL association

576 tests. Additional methylation PCs were not included in association tests, as they were significantly

577 correlated with asthma phenotypes. Associations with FDR-adjusted P<0.05 were considered significant.

578 MeQTL analysis with the PBMC data included sex, collection site, plate, ancestry PCs 1-3, and eight

579 latent factors [152] (protecting for FEV_1 at age 7) as covariates.

580 To test CpG site methylation associations with lung function in NECs, we performed linear

regressions on the most recent FEV₁ measures, with age, sex, ancestry PCs 1-3, and methylation PCs 1-3

as covariates. For the PBMC analysis, we set FEV_1 at age 7 as the dependent variable, with sex, collection

583 site, plate, ancestry PCs 1-3, and latent factors included as covariates.

584 For association testing with smoking exposures, we ran linear regressions for DNA methylation 585 and lung function in NECs and PBMCs, as described above, with the addition of cotinine concentrations 586 as a predictor. We further tested for smoking-by-genotype interaction effects on DNA methylation and 587 lung function using these models by adding an interaction term (cotinine concentration : rs10220464 588 genotype). Proportions of explained variance were calculated by squaring partial correlation coefficients

- of regression model predictors [153]. One sample from one sibling pair was removed from all methylation
 analyses to prevent confounding due to relatedness.
- 591

592 Mendelian Randomization and Mediation Analysis

593 To assess the causal effects of DNA methylation on lung function, we performed one-sample Mendelian 594 randomization analysis. We applied a 2SLS regression to URECA samples with WGS and DNA 595 methylation data (n=285) using ivreg [154]. DNA methylation levels in NECs at the cg03306306 CpG 596 site were first adjusted for methylation PCs 1-3 and used as the endogenous, exposure variable. The 597 adjusted and normalized FEV₁ values from the GWAS were set as the dependent outcome variable. Urine 598 cotinine levels were included as an exogenous covariate (included in both stages). The instrumental 599 variables were chosen from a set of candidate SNPs that were at least nominally associated with 600 cg03306306 methylation with p<0.15. Clustering of pairwise linkage disequilibrium values between these 601 SNPs revealed six distinct haplotypes (S14 Fig). To ensure instrument exogeneity, each candidate SNP 602 was tested for association with FEV_1 after conditioning on cg03306306 methylation and urine cotinine, 603 and SNPs associated with p<0.05 were removed from consideration. Of the remaining candidate SNPs, 604 one was chosen from each haplotype, resulting in an instrument composed of 4 SNPs (rs11160777, 605 rs137961671, rs7143936, rs11160776). Instrument relevance was validated using the F test, endogeneity 606 using the Wu-Hausman test, and instrument exogeneity using the Sargon test. We tested two 2SLS 607 models: one where the instrumental variables were included as individual predictors, and another 608 featuring an unweighted allele score of the four instrumental variants to reduce potential bias from weak 609 instruments and/or winner's curse [155,156]. 610 Mediation analysis was conducted with ROBMED [157]. The adjusted and normalized FEV_1 611 residuals were set as the dependent variable, adjusted cg03306306 methylation as the mediator, and 612 rs10220464 as the independent variable. Age at FEV1 measurement, sex, asthma status, ancestry PCs 1-3,

613 and urine cotinine levels were included as covariates. We also performed a secondary mediation analysis

614 without adjusting for asthma status. To identify additional, potential confounders that could invalidate our

615	mediation model, we systematically tested for associations with 2 socioeconomic variables and 11
616	environmental exposures available in APIC and URECA (S8 Table, S15 Fig). For each environmental
617	exposure, we tested whether the variable was associated with the mediator (cg03306306) and whether the
618	variable was associated with the outcome (FEV_1) conditional on the mediator. To ensure no exposure-
619	mediator interactions, we repeated the cg03306306 association test with FEV_1 with rs10220464 included
620	as a predictor with a rs10220464: cg03306306 interaction term. The indirect effect of rs10220464 on
621	FEV ₁ via cg03306306 methylation was estimated using 100,000 bootstrap resamples.
622	
623	Gene Expression Analysis
624	We analyzed gene expression in NECs and PBMCs from the URECA birth cohort using RNA-seq. The
625	NEC data were derived from 323 children (155 females, 168 males) at age 11 years at the time of sample
626	collection, and the PBMC data were derived from 130 (53 females, 77 males) PBMC children aged 2
627	years at the time of collection. Sequencing reads were mapped and quantified using STAR (v2.6.1) [158]
628	and samples underwent trimmed means of M-value (TMM) normalization and voom transformation
629	[159]. Genes with <1 count per million mapped reads (CPM) were removed from analysis. For eQTL
630	association testing in NECs we corrected for sex, the first three ancestral PCs, collection site, epithelial
631	cell proportion, sequencing batch, and 14 latent factors [152] using limma [160]. In PBMCs, we corrected
632	for sex, the first three ancestral PCs, collection site, and 19 latent factors.

633

634 Chromatin Interaction Analysis

635 Chromatin interactions were assessed using promoter capture Hi-C [161,162] in ex vivo human BECs

from 8 adult lung donors, including 4 with asthma. The data was processed and analyzed as previously

637 described [72,163]. Chromosomal interactions were evaluated using the CHiCAGO algorithm [164].

638 Interactions with CHiCAGO scores ≥ 5 were considered significant [164]. Genetic variants within 1 kb of

a given interacting fragment were considered part of the chromatin loop. Genes that were not expressed in

640 NECs were not included in the analysis.

641 DATA AVAILABILITY

64	-2	Phenotype, genotype,	GWAS	summary	v statistics,	and whole-	genome se	quencing	files are	available ir	ı
				2	,		0				

- 643 dbGaP under accession **phs002921.v1.p1**. The URECA gene expression data are available on the Gene
- 644 Expression Omnibus (GEO) under the accession GSE145505 (NECs) and GSE96783 (PBMCs). The
- 645 pcHi-C data are available in GEO under the reference series GSE152550. The DNA methylation data will
- be deposited to GEO (Morin, et al. A Functional Genomics Pipeline to Identify High-Value Asthma and
- 647 Allergy CpGs in the Human Methylome. medRxiv. 2022:2022.05.19.22275204).
- 648

649 ACKNOWLEDGEMENTS

650 We are grateful to all participants and their families who took part in these studies. We would like to

extend special thanks to Pieter Faber and the University of Chicago Genomics Facility, as well as to Petra

652 LeBeau and Rebecca Z. Krouse, formerly of Rho Inc., for their respective contributions.

653

654 FUNDING

- This work was supported by NIH grants U19 AI62310, HHSN272200900052C, HHSN272201000052I,
- 656 UM1 AI114271, UG3 OD023282, and UM1 AI160040. Site data collection was supported by the
- 657 following NIH grants: RR00052, UL1 TR001079 (Baltimore); M01 RR00533, UL1 RR025771, 1 UL1
- 658 TR001430 (Boston); UL1 TR000150 (Chicago); UL1 TR000451, UL1 TR001105 (Dallas); Ul1
- 659 RR025780 (Denver); UL1 TR000040, M01 RR00071, UL1 RR024156 (New York); UL1 TR000075
- 660 (D.C.); UL1 TR000077 (Cincinnati). M.D. was supported by TL1 TR002388 and T32 HL007605.
- 661

662 AUTHOR CONTRIBUTIONS

- M.D., W.W.B., P.B., D.N., G.T.O., J.E.G., D.J.J., C.O. made contributions to the conception and/or
- design of the study. M.D., E.T., and S.C. performed computational analyses. E.T. prepared samples for
- 665 'omic analyses. W.W-S. oversaw 'omic data management. C.M.V. and A.C. oversaw clinical data
- 666 management. J.E.S., D.G., G.T.O., J.E.G., D.J.J., C.O. contributed to interpretation of results. R.A.W.,

M.M., G.N.K.H., M.G.S., R.S.G, M.A.G., A.H.L., H.K., M.K., L.B.B., D.S., M.C.A. contributed patient
samples and/or data. M.D. wrote the manuscript. All authors read and approved the manuscript.

670 **DISCLOSURES**

671 All authors, with the exception of M. Altman and P. Becker, report grants from NIH/NIAID during the 672 conduct of study. M. Dapas, C. Visness, A. Calatroni and P. Becker have nothing to disclose outside the 673 submitted work. C. Ober reports personal fees from American Association of Asthma, Allergy and 674 Immunology, outside the submitted work. M. Altman reports personal fees from Sanofi-Regeneron 675 outside the submitted work. W. Busse reports personal fees from Boston Scientific, Novartis, Glaxo 676 SmithKline, Genentech, Sanofi/Genzyme, AstraZeneca, Teva, Regeneron and Elsevier outside the 677 submitted work. M. Gill reports an honorarium for and support for travel to the 2017 AAAAI meeting 678 during the conduct of study and monetary compensation from the American Academy of Pediatrics for 679 her work teaching the biannual Pediatrics board review course, PREP The Course. K. Hershey reports 680 grants from Adare, during the conduct of the study. D. Jackson reports personal fees from Novartis, 681 Boehringer Ingelheim, Pfizer, Regeneron, AstraZeneca, Sanofi and Vifor Pharma, grants and personal 682 fees from GlaxoSmithKline and grants from NIH/NHLBI, outside the submitted work. M. Kattan reports 683 personal fees from Regeneron, outside the submitted work. R. Gruchalla reports government employment 684 from Center for Biologics Evaluation and Research as well as personal fees from Consulting 685 Massachusetts Medical Society, outside the submitted work. A. Liu reports personal fees from Phadia 686 ThermoFisher as consulting honoraria, grants and non-financial support from ResMed/Propeller Health, 687 non-financial support from Revenio, grants and personal fees from Avillion and personal fees from 688 Labcorp, outside the submitted work. L. Bacharier reports personal fees from GlaxoSmithKline, 689 Genentech/Novartis, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, 690 Sanofi/Regeneron, Vectura and geCircassia and personal fees and non-financial support from 691 Merckoutside the submitted work. J. Gern reports personal fees from AstraZeneca and Gossamer Bio and 692 personal fees and stock options from Meissa Vaccines Inc, outside the submitted work. In addition, Dr.

- 693 Gern has a patent Methods of Propagating Rhinovirus C in Previously Unsusceptible Cell Lines issued,
- and a patent Adapted Rhinovirus C issued. G. O'Connor reports personal fees from AstraZeneca and
- 695 grants from Janssen Pharmaceuticals, outside the submitted work. R. Wood reports grants from DBV,
- Aimmune, Astellas, HAL-Allergy and Regeneron and royalties from Up to Date, outsite the submitted
- 697 work. Dr. Becker's co-authorship of this publication does not necessarily constitute endorsement by the
- 698 National Institute of Allergy and Infectious Diseases, the National Institutes of Health or any other agency
- 699 of the United States government.

700

701 **REFERENCES**

- Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313(7059):711-5; discussion 5-6.
- Schunemann HJ, Dorn J, Grant BJ, Winkelstein W, Jr., Trevisan M. Pulmonary function is
 a long-term predictor of mortality in the general population: 29-year follow-up of the
 Buffalo Health Study. Chest. 2000;118(3):656-64.
- Mannino DM, Holguin F, Pavlin BI, Ferdinands JM. Risk factors for prevalence of and
 mortality related to restriction on spirometry: findings from the First National Health and
 Nutrition Examination Survey and follow-up. Int J Tuberc Lung Dis. 2005;9(6):613-21.
- Chinn S, Gislason T, Aspelund T, Gudnason V. Optimum expression of adult lung function
 based on all-cause mortality: results from the Reykjavik study. Respir Med.
 2007;101(3):601-9.
- 5. Miller MR, Pedersen OF, Lange P, Vestbo J. Improved survival prediction from lung
 function data in a large population sample. Respir Med. 2009;103(3):442-8.
- Agusti A, Noell G, Brugada J, Faner R. Lung function in early adulthood and health in later
 life: a transgenerational cohort analysis. Lancet Respir Med. 2017;5(12):935-45.
- 718 7. Stern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early
 719 infancy and lung function by age 22 years: a non-selective longitudinal cohort study.
 720 Lancet. 2007;370(9589):758-64.
- 8. Stocks J, Hislop A, Sonnappa S. Early lung development: lifelong effect on respiratory
 health and disease. Lancet Respir Med. 2013;1(9):728-42.
- 9. McGeachie MJ, Yates KP, Zhou X, Guo F, Sternberg AL, Van Natta ML, et al. Patterns of
 Growth and Decline in Lung Function in Persistent Childhood Asthma. N Engl J Med.
 2016;374(19):1842-52.
- Agusti A, Faner R. Lung function trajectories in health and disease. Lancet Respir Med.
 2019;7(4):358-64.
- Bisgaard H, Jensen SM, Bonnelykke K. Interaction between asthma and lung function
 growth in early life. Am J Respir Crit Care Med. 2012;185(11):1183-9.
- Duijts L, Reiss IK, Brusselle G, de Jongste JC. Early origins of chronic obstructive lung
 diseases across the life course. Eur J Epidemiol. 2014;29(12):871-85.
- 13. Klimentidis YC, Vazquez AI, de Los Campos G, Allison DB, Dransfield MT, Thannickal
 VJ. Heritability of pulmonary function estimated from pedigree and whole-genome
 markers. Front Genet. 2013;4:174.

- Wilk JB, Chen TH, Gottlieb DJ, Walter RE, Nagle MW, Brandler BJ, et al. A genomewide association study of pulmonary function measures in the Framingham Heart Study.
 PLoS Genet. 2009;5(3):e1000429.
- Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, Obeidat M, et al. Genome-wide
 association study identifies five loci associated with lung function. Nat Genet.
 2010;42(1):36-44.
- Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, et al. Metaanalyses of genome-wide association studies identify multiple loci associated with
 pulmonary function. Nat Genet. 2010;42(1):45-52.
- 744 17. Soler Artigas M, Loth DW, Wain LV, Gharib SA, Obeidat M, Tang W, et al. Genome-wide
 745 association and large-scale follow up identifies 16 new loci influencing lung function. Nat
 746 Genet. 2011;43(11):1082-90.
- Yao TC, Du G, Han L, Sun Y, Hu D, Yang JJ, et al. Genome-wide association study of
 lung function phenotypes in a founder population. J Allergy Clin Immunol.
 2014;133(1):248-55 e1-10.
- Loth DW, Soler Artigas M, Gharib SA, Wain LV, Franceschini N, Koch B, et al. Genomewide association analysis identifies six new loci associated with forced vital capacity. Nat
 Genet. 2014;46(7):669-77.
- Wain LV, Shrine N, Artigas MS, Erzurumluoglu AM, Noyvert B, Bossini-Castillo L, et al.
 Genome-wide association analyses for lung function and chronic obstructive pulmonary
 disease identify new loci and potential druggable targets. Nat Genet. 2017;49(3):416-25.
- Burkart KM, Sofer T, London SJ, Manichaikul A, Hartwig FP, Yan Q, et al. A GenomeWide Association Study in Hispanics/Latinos Identifies Novel Signals for Lung Function.
 The Hispanic Community Health Study/Study of Latinos. Am J Respir Crit Care Med.
 2018;198(2):208-19.
- Wyss AB, Sofer T, Lee MK, Terzikhan N, Nguyen JN, Lahousse L, et al. Multiethnic
 meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function.
 Nat Commun. 2018;9(1):2976.
- Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, et al.
 New genetic signals for lung function highlight pathways and chronic obstructive
 pulmonary disease associations across multiple ancestries. Nat Genet. 2019;51(3):481-93.
- Akenroye AT, Brunetti T, Romero K, Daya M, Kanchan K, Shankar G, et al. Genome-wide
 association study of asthma, total IgE, and lung function in a cohort of Peruvian children. J
 Allergy Clin Immunol. 2021. doi: 10.1016/j.jaci.2021.02.035.
- Zhu Z, Li J, Si J, Ma B, Shi H, Lv J, et al. A large-scale genome-wide association analysis
 of lung function in the Chinese population identifies novel loci and highlights shared
 genetic aetiology with obesity. Eur Respir J. 2021;58(4).

- Obeidat M, Hao K, Bosse Y, Nickle DC, Nie Y, Postma DS, et al. Molecular mechanisms
 underlying variations in lung function: a systems genetics analysis. Lancet Respir Med.
 2015;3(10):782-95.
- 27. Gharib SA, Loth DW, Soler Artigas M, Birkland TP, Wilk JB, Wain LV, et al. Integrative
 pathway genomics of lung function and airflow obstruction. Hum Mol Genet.
 2015;24(23):6836-48.
- Portas L, Pereira M, Shaheen SO, Wyss AB, London SJ, Burney PGJ, et al. Lung
 Development Genes and Adult Lung Function. Am J Respir Crit Care Med.
 2020;202(6):853-65.
- 781 29. Kheirallah AK, Miller S, Hall IP, Sayers I. Translating Lung Function Genome-Wide
 782 Association Study (GWAS) Findings: New Insights for Lung Biology. Adv Genet.
 783 2016;93:57-145.
- 30. Aschard H, Tobin MD, Hancock DB, Skurnik D, Sood A, James A, et al. Evidence for
 large-scale gene-by-smoking interaction effects on pulmonary function. Int J Epidemiol.
 2017;46(3):894-904.
- 787 31. Park B, An J, Kim W, Kang HY, Koh SB, Oh B, et al. Effect of 6p21 region on lung
 788 function is modified by smoking: a genome-wide interaction study. Sci Rep.
 789 2020;10(1):13075.
- Kim W, Moll M, Qiao D, Hobbs BD, Shrine N, Sakornsakolpat P, et al. Smoking
 Interaction with a Polygenic Risk Score for Reduced Lung Function. medRxiv. 2021. doi:
 10.1101/2021.03.26.21254415:2021.03.26.21254415.
- 33. Melbourne CA, Erzurumluoglu AM, Shrine N, Chen J, Tobin MD, Hansell A, et al.
 Genome-wide gene-air pollution interaction analysis of lung function in 300,000
 individuals. medRxiv. 2021. doi: 10.1101/2021.06.03.21256376:2021.06.03.21256376.
- 34. Miller MD, Marty MA. Impact of environmental chemicals on lung development. Environ
 Health Perspect. 2010;118(8):1155-64.
- Decrue F, Gorlanova O, Usemann J, Frey U. Lung functional development and asthma trajectories. Semin Immunopathol. 2020;42(1):17-27.
- 36. He Z, Wu H, Zhang S, Lin Y, Li R, Xie L, et al. The association between secondhand
 smoke and childhood asthma: A systematic review and meta-analysis. Pediatr Pulmonol.
 2020;55(10):2518-31.
- 37. Thacher JD, Schultz ES, Hallberg J, Hellberg U, Kull I, Thunqvist P, et al. Tobacco smoke
 exposure in early life and adolescence in relation to lung function. Eur Respir J.
 2018;51(6).

806 807 808	38.	Dratva J, Zemp E, Dharmage SC, Accordini S, Burdet L, Gislason T, et al. Early Life Origins of Lung Ageing: Early Life Exposures and Lung Function Decline in Adulthood in Two European Cohorts Aged 28-73 Years. PLoS One. 2016;11(1):e0145127.
809 810	39.	Savran O, Ulrik CS. Early life insults as determinants of chronic obstructive pulmonary disease in adult life. Int J Chron Obstruct Pulmon Dis. 2018;13:683-93.
811 812 813	40.	Zeilinger S, Kuhnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, et al. Tobacco smoking leads to extensive genome-wide changes in DNA methylation. PLoS One. 2013;8(5):e63812.
814 815	41.	Rider CF, Carlsten C. Air pollution and DNA methylation: effects of exposure in humans. Clin Epigenetics. 2019;11(1):131.
816 817 818	42.	Jamieson E, Korologou-Linden R, Wootton RE, Guyatt AL, Battram T, Burrows K, et al. Smoking, DNA Methylation, and Lung Function: a Mendelian Randomization Analysis to Investigate Causal Pathways. Am J Hum Genet. 2020;106(3):315-26.
819 820 821	43.	Kwak SY, Park CY, Shin MJ. Smoking May Affect Pulmonary Function through DNA Methylation: an Epigenome-Wide Association Study in Korean Men. Clin Nutr Res. 2020;9(2):134-44.
822 823	44.	Sunny SK, Zhang H, Relton CL, Ring S, Kadalayil L, Mzayek F, et al. Sex-specific longitudinal association of DNA methylation with lung function. ERJ Open Res. 2021;7(3).
824 825 826 827	45.	Mukherjee N, Lockett GA, Merid SK, Melen E, Pershagen G, Holloway JW, et al. DNA methylation and genetic polymorphisms of the Leptin gene interact to influence lung function outcomes and asthma at 18 years of age. Int J Mol Epidemiol Genet. 2016;7(1):1-17.
828 829 830	46.	Zhang H, Tong X, Holloway JW, Rezwan FI, Lockett GA, Patil V, et al. The interplay of DNA methylation over time with Th2 pathway genetic variants on asthma risk and temporal asthma transition. Clin Epigenetics. 2014;6(1):8.
831 832 833	47.	Munoz-Pizza DM, Villada-Canela M, Reyna MA, Texcalac-Sangrador JL, Osornio-Vargas AR. Air pollution and children's respiratory health: a scoping review of socioeconomic status as an effect modifier. Int J Public Health. 2020;65(5):649-60.
834 835 836	48.	Hajizadeh M, Nandi A. The socioeconomic gradient of secondhand smoke exposure in children: evidence from 26 low-income and middle-income countries. Tob Control. 2016;25(e2):e146-e55.
837 838 839 840	49.	Martinez CH, Mannino DM, Curtis JL, Han MK, Diaz AA. Socioeconomic Characteristics Are Major Contributors to Ethnic Differences in Health Status in Obstructive Lung Disease: An Analysis of the National Health and Nutrition Examination Survey 2007-2010. Chest. 2015;148(1):151-8.

Thakur N, Oh SS, Nguyen EA, Martin M, Roth LA, Galanter J, et al. Socioeconomic status
and childhood asthma in urban minority youths. The GALA II and SAGE II studies. Am J
Respir Crit Care Med. 2013;188(10):1202-9.

- St. Oraka E, Iqbal S, Flanders WD, Brinker K, Garbe P. Racial and ethnic disparities in current asthma and emergency department visits: findings from the National Health Interview
 Survey, 2001-2010. J Asthma. 2013;50(5):488-96.
- Keet CA, Matsui EC, McCormack MC, Peng RD. Urban residence, neighborhood poverty,
 race/ethnicity, and asthma morbidity among children on Medicaid. J Allergy Clin
 Immunol. 2017;140(3):822-7.
- 850 53. Manrai AK, Funke BH, Rehm HL, Olesen MS, Maron BA, Szolovits P, et al. Genetic
 851 Misdiagnoses and the Potential for Health Disparities. N Engl J Med. 2016;375(7):655-65.
- Landry LG, Ali N, Williams DR, Rehm HL, Bonham VL. Lack Of Diversity In Genomic
 Databases Is A Barrier To Translating Precision Medicine Research Into Practice. Health
 Aff (Millwood). 2018;37(5):780-5.
- 855 55. Pongracic JA, Krouse RZ, Babineau DC, Zoratti EM, Cohen RT, Wood RA, et al.
 856 Distinguishing characteristics of difficult-to-control asthma in inner-city children and
 857 adolescents. J Allergy Clin Immunol. 2016;138(4):1030-41.
- Solution Schlaussen Schl
- Solution
 Sol
- 863 58. Zhou X, Stephens M. Genome-wide efficient mixed-model analysis for association studies.
 864 Nat Genet. 2012;44(7):821-4.
- Solution Sol
- Ma M, Ru Y, Chuang LS, Hsu NY, Shi LS, Hakenberg J, et al. Disease-associated variants
 in different categories of disease located in distinct regulatory elements. BMC Genomics.
 2015;16 Suppl 8:S3.
- 871 61. Boyle EA, Li YI, Pritchard JK. An Expanded View of Complex Traits: From Polygenic to
 872 Omnigenic. Cell. 2017;169(7):1177-86.
- 873 62. Watanabe K, Stringer S, Frei O, Umicevic Mirkov M, de Leeuw C, Polderman TJC, et al.
 874 A global overview of pleiotropy and genetic architecture in complex traits. Nat Genet.
 875 2019;51(9):1339-48.

876 877 878	63.	Schulz H, Ruppert AK, Herms S, Wolf C, Mirza-Schreiber N, Stegle O, et al. Genome- wide mapping of genetic determinants influencing DNA methylation and gene expression in human hippocampus. Nat Commun. 2017;8(1):1511.
879 880 881	64.	Huan T, Joehanes R, Song C, Peng F, Guo Y, Mendelson M, et al. Genome-wide identification of DNA methylation QTLs in whole blood highlights pathways for cardiovascular disease. Nat Commun. 2019;10(1):4267.
882 883 884 885	65.	Hannon E, Gorrie-Stone TJ, Smart MC, Burrage J, Hughes A, Bao Y, et al. Leveraging DNA-Methylation Quantitative-Trait Loci to Characterize the Relationship between Methylomic Variation, Gene Expression, and Complex Traits. Am J Hum Genet. 2018;103(5):654-65.
886 887 888	66.	McKennan C, Naughton K, Stanhope C, Kattan M, O'Connor GT, Sandel MT, et al. Longitudinal data reveal strong genetic and weak non-genetic components of ethnicity- dependent blood DNA methylation levels. Epigenetics. 2021;16(6):662-76.
889 890 891	67.	Joubert BR, Felix JF, Yousefi P, Bakulski KM, Just AC, Breton C, et al. DNA Methylation in Newborns and Maternal Smoking in Pregnancy: Genome-wide Consortium Meta- analysis. Am J Hum Genet. 2016;98(4):680-96.
892 893 894	68.	Sikdar S, Joehanes R, Joubert BR, Xu CJ, Vives-Usano M, Rezwan FI, et al. Comparison of smoking-related DNA methylation between newborns from prenatal exposure and adults from personal smoking. Epigenomics. 2019;11(13):1487-500.
895 896 897	69.	Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 2010;6(4):e1000888.
898 899	70.	Yao DW, O'Connor LJ, Price AL, Gusev A. Quantifying genetic effects on disease mediated by assayed gene expression levels. Nat Genet. 2020;52(6):626-33.
900 901	71.	Hormozdiari F, van de Bunt M, Segre AV, Li X, Joo JWJ, Bilow M, et al. Colocalization of GWAS and eQTL Signals Detects Target Genes. Am J Hum Genet. 2016;99(6):1245-60.
902 903 904	72.	Helling BA, Sobreira DR, Hansen GT, Sakabe NJ, Luo K, Billstrand C, et al. Altered transcriptional and chromatin responses to rhinovirus in bronchial epithelial cells from adults with asthma. Commun Biol. 2020;3(1):678.
905 906 907	73.	Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 2001;8(4):781-94.
908 909 910	74.	Aylon Y, Ofir-Rosenfeld Y, Yabuta N, Lapi E, Nojima H, Lu X, et al. The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1. Genes Dev. 2010;24(21):2420-9.

911 75. Wang Y, Godin-Heymann N, Dan Wang X, Bergamaschi D, Llanos S, Lu X. ASPP1 and
912 ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer
913 cells. Cell Death Differ. 2013;20(4):525-34.

- 76. Xue H, Li MX. MicroRNA-150 protects against cigarette smoke-induced lung
 inflammation and airway epithelial cell apoptosis through repressing p53: MicroRNA-150
 in CS-induced lung inflammation. Hum Exp Toxicol. 2018;37(9):920-8.
- 77. Xu F, Xu A, Guo Y, Bai Q, Wu X, Ji SP, et al. PM2.5 exposure induces alveolar epithelial
 cell apoptosis and causes emphysema through p53/Siva-1. Eur Rev Med Pharmacol Sci.
 2020;24(7):3943-50.
- 920 78. Song Q, Zhou ZJ, Cai S, Chen Y, Chen P. Oxidative stress links the tumour suppressor p53
 921 with cell apoptosis induced by cigarette smoke. Int J Environ Health Res. 2021. doi:
 922 10.1080/09603123.2021.1910211:1-11.
- 79. Zhao K, Yu M, Zhu Y, Liu D, Wu Q, Hu Y. EGR-1/ASPP1 inter-regulatory loop promotes apoptosis by inhibiting cyto-protective autophagy. Cell Death Dis. 2017;8(6):e2869.
- 80. Reynolds PR, Cosio MG, Hoidal JR. Cigarette smoke-induced Egr-1 upregulates
 proinflammatory cytokines in pulmonary epithelial cells. Am J Respir Cell Mol Biol.
 2006;35(3):314-9.
- 81. Chen ZH, Kim HP, Sciurba FC, Lee SJ, Feghali-Bostwick C, Stolz DB, et al. Egr-1
 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease.
 PLoS One. 2008;3(10):e3316.
- 82. Shen N, Gong T, Wang JD, Meng FL, Qiao L, Yang RL, et al. Cigarette smoke-induced
 pulmonary inflammatory responses are mediated by EGR-1/GGPPS/MAPK signaling. Am
 J Pathol. 2011;178(1):110-8.
- 83. Wang SB, Zhang C, Xu XC, Xu F, Zhou JS, Wu YP, et al. Early growth response factor 1
 is essential for cigarette smoke-induced MUC5AC expression in human bronchial
 epithelial cells. Biochem Biophys Res Commun. 2017;490(2):147-54.
- 84. Xu F, Cao J, Luo M, Che L, Li W, Ying S, et al. Early growth response gene 1 is essential
 for urban particulate matter-induced inflammation and mucus hyperproduction in airway
 epithelium. Toxicol Lett. 2018;294:145-55.
- 85. Golebski K, Gorenjak M, Kabesch M, Maitland-Van Der Zee A-H, Melén E, Potočnik U,
 et al. EGR-1 as a potential biomarker in asthma and proinflammatory responses in airway
 epithelium. European Respiratory Journal. 2021;58(suppl 65):PA2041.
- 86. Wang A, Chiou J, Poirion OB, Buchanan J, Valdez MJ, Verheyden JM, et al. Single-cell
 multiomic profiling of human lungs reveals cell-type-specific and age-dynamic control of
 SARS-CoV2 host genes. Elife. 2020;9.

946 947	87.	Karlsson M, Zhang C, Mear L, Zhong W, Digre A, Katona B, et al. A single-cell type transcriptomics map of human tissues. Sci Adv. 2021;7(31).
948 949 950	88.	Cheng Y, Luo W, Li Z, Cao M, Zhu Z, Han C, et al. CircRNA-012091/PPP1R13B- mediated Lung Fibrotic Response in Silicosis via Endoplasmic Reticulum Stress and Autophagy. Am J Respir Cell Mol Biol. 2019;61(3):380-91.
951 952	89.	Vigneron AM, Ludwig RL, Vousden KH. Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. Genes Dev. 2010;24(21):2430-9.
953 954	90.	Manfredi JJ. An identity crisis for a cancer gene: subcellular location determines ASPP1 function. Cancer Cell. 2010;18(5):409-10.
955 956	91.	Fogal V, Kartasheva NN, Trigiante G, Llanos S, Yap D, Vousden KH, et al. ASPP1 and ASPP2 are new transcriptional targets of E2F. Cell Death Differ. 2005;12(4):369-76.
957 958 959	92.	Zhou SJ, Li M, Zeng DX, Zhu ZM, Hu XW, Li YH, et al. Expression variations of connective tissue growth factor in pulmonary arteries from smokers with and without chronic obstructive pulmonary disease. Sci Rep. 2015;5:8564.
960 961 962 963	93.	Eguchi A, Nishizawa-Jotaki S, Tanabe H, Rahmutulla B, Watanabe M, Miyaso H, et al. An Altered DNA Methylation Status in the Human Umbilical Cord Is Correlated with Maternal Exposure to Polychlorinated Biphenyls. Int J Environ Res Public Health. 2019;16(15).
964 965 966	94.	Pierce BL, Tong L, Argos M, Demanelis K, Jasmine F, Rakibuz-Zaman M, et al. Co- occurring expression and methylation QTLs allow detection of common causal variants and shared biological mechanisms. Nat Commun. 2018;9(1):804.
967 968 969	95.	Philibert RA, Sears RA, Powers LS, Nash E, Bair T, Gerke AK, et al. Coordinated DNA methylation and gene expression changes in smoker alveolar macrophages: specific effects on VEGF receptor 1 expression. J Leukoc Biol. 2012;92(3):621-31.
970 971 972	96.	Guijo M, Ceballos-Chavez M, Gomez-Marin E, Basurto-Cayuela L, Reyes JC. Expression of TDRD9 in a subset of lung carcinomas by CpG island hypomethylation protects from DNA damage. Oncotarget. 2018;9(11):9618-31.
973 974	97.	Consortium GT. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580-5.
975 976 977	98.	Lokk K, Modhukur V, Rajashekar B, Martens K, Magi R, Kolde R, et al. DNA methylome profiling of human tissues identifies global and tissue-specific methylation patterns. Genome Biol. 2014;15(4):r54.
978 979 980	99.	Wan J, Oliver VF, Wang G, Zhu H, Zack DJ, Merbs SL, et al. Characterization of tissue- specific differential DNA methylation suggests distinct modes of positive and negative gene expression regulation. BMC Genomics. 2015;16:49.
- 981 100. den Dekker HT, Burrows K, Felix JF, Salas LA, Nedeljkovic I, Yao J, et al. Newborn
 982 DNA-methylation, childhood lung function, and the risks of asthma and COPD across the
 983 life course. Eur Respir J. 2019;53(4).
- 101. Imboden M, Wielscher M, Rezwan FI, Amaral AFS, Schaffner E, Jeong A, et al.
 Epigenome-wide association study of lung function level and its change. Eur Respir J.
 2019;54(1).
- 987 102. Mukherjee N, Arathimos R, Chen S, Kheirkhah Rahimabad P, Han L, Zhang H, et al. DNA
 988 methylation at birth is associated with lung function development until age 26 years. Eur
 989 Respir J. 2021;57(4).
- 103. Wang T, Wang W, Li W, Duan H, Xu C, Tian X, et al. Genome-wide DNA methylation
 analysis of pulmonary function in middle and old-aged Chinese monozygotic twins. Respir
 Res. 2021;22(1):300.
- 104. Herrera-Luis E, Li A, Mak ACY, Perez-Garcia J, Elhawary JR, Oh SS, et al. Epigenomewide association study of lung function in Latino children and youth with asthma. Clin
 Epigenetics. 2022;14(1):9.
- 105. Cosin-Tomas M, Bustamante M, Sunyer J. Epigenetic association studies at birth and the
 origin of lung function development. Eur Respir J. 2021;57(4).
- 106. Yang IV, Lozupone CA, Schwartz DA. The environment, epigenome, and asthma. J
 Allergy Clin Immunol. 2017;140(1):14-23.
- 1000 107. Lin PI, Shu H, Mersha TB. Comparing DNA methylation profiles across different tissues
 associated with the diagnosis of pediatric asthma. Sci Rep. 2020;10(1):151.
- 1002 108. Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and Scope. Cold
 1003 Spring Harb Perspect Med. 2022;12(1).
- 1004 109. Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects.
 1005 Epidemiology. 1992;3(2):143-55.
- 1006 110. Li YF, Gilliland FD, Berhane K, McConnell R, Gauderman WJ, Rappaport EB, et al.
 1007 Effects of in utero and environmental tobacco smoke exposure on lung function in boys and girls with and without asthma. Am J Respir Crit Care Med. 2000;162(6):2097-104.
- 1009 111. Gilliland FD, Berhane K, Li YF, Rappaport EB, Peters JM. Effects of early onset asthma
 1010 and in utero exposure to maternal smoking on childhood lung function. Am J Respir Crit
 1011 Care Med. 2003;167(6):917-24.
- 1012 112. Schultz ES, Litonjua AA, Melen E. Effects of Long-Term Exposure to Traffic-Related Air
 1013 Pollution on Lung Function in Children. Curr Allergy Asthma Rep. 2017;17(6):41.
- 1014 113. Kreiner-Moller E, Bisgaard H, Bonnelykke K. Prenatal and postnatal genetic influence on
 1015 lung function development. J Allergy Clin Immunol. 2014;134(5):1036-42 e15.

1016 1017 1018	114.	Lee EY, Mak ACY, Hu D, Sajuthi S, White MJ, Keys KL, et al. Whole-Genome Sequencing Identifies Novel Functional Loci Associated with Lung Function in Puerto Rican Youth. Am J Respir Crit Care Med. 2020;202(7):962-72.
1019 1020 1021	115.	Goddard PC, Keys KL, Mak ACY, Lee EY, Liu AK, Samedy-Bates LA, et al. Integrative genomic analysis in African American children with asthma finds three novel loci associated with lung function. Genet Epidemiol. 2021;45(2):190-208.
1022 1023 1024	116.	Akenroye AT, Brunetti T, Romero K, Daya M, Kanchan K, Shankar G, et al. Genome-wide association study of asthma, total IgE, and lung function in a cohort of Peruvian children. J Allergy Clin Immunol. 2021;148(6):1493-504.
1025 1026 1027	117.	Imboden M, Bouzigon E, Curjuric I, Ramasamy A, Kumar A, Hancock DB, et al. Genome- wide association study of lung function decline in adults with and without asthma. J Allergy Clin Immunol. 2012;129(5):1218-28.
1028 1029 1030	118.	Aschard H, Vilhjalmsson BJ, Joshi AD, Price AL, Kraft P. Adjusting for heritable covariates can bias effect estimates in genome-wide association studies. Am J Hum Genet. 2015;96(2):329-39.
1031 1032	119.	Jones MJ, Goodman SJ, Kobor MS. DNA methylation and healthy human aging. Aging Cell. 2015;14(6):924-32.
1033 1034 1035	120.	Ambatipudi S, Cuenin C, Hernandez-Vargas H, Ghantous A, Le Calvez-Kelm F, Kaaks R, et al. Tobacco smoking-associated genome-wide DNA methylation changes in the EPIC study. Epigenomics. 2016;8(5):599-618.
1036 1037 1038	121.	Tommasi S, Zheng A, Besaratinia A. Exposure of mice to secondhand smoke elicits both transient and long-lasting transcriptional changes in cancer-related functional networks. Int J Cancer. 2015;136(10):2253-63.
1039 1040 1041	122.	Sridhar S, Schembri F, Zeskind J, Shah V, Gustafson AM, Steiling K, et al. Smoking- induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium. BMC Genomics. 2008;9:259.
1042 1043 1044	123.	Zhang X, Sebastiani P, Liu G, Schembri F, Zhang X, Dumas YM, et al. Similarities and differences between smoking-related gene expression in nasal and bronchial epithelium. Physiol Genomics. 2010;41(1):1-8.
1045 1046 1047	124.	Brugha R, Lowe R, Henderson AJ, Holloway JW, Rakyan V, Wozniak E, et al. DNA methylation profiles between airway epithelium and proxy tissues in children. Acta Paediatr. 2017;106(12):2011-6.
1048 1049 1050	125.	Imkamp K, Berg M, Vermeulen CJ, Heijink IH, Guryev V, Kerstjens HAM, et al. Nasal epithelium as a proxy for bronchial epithelium for smoking-induced gene expression and expression Quantitative Trait Loci. J Allergy Clin Immunol. 2018;142(1):314-7 e15.

126. Kicic A, de Jong E, Ling KM, Nichol K, Anderson D, Wark PAB, et al. Assessing the

1051

1052 unified airway hypothesis in children via transcriptional profiling of the airway epithelium. 1053 J Allergy Clin Immunol. 2020;145(6):1562-73. 1054 127. Bergougnoux A, Claustres M, De Sario A. Nasal epithelial cells: a tool to study DNA 1055 methylation in airway diseases. Epigenomics. 2015;7(1):119-26. 1056 128. Gergen PJ, Teach SJ, Togias A, Busse WW. Reducing Exacerbations in the Inner City: 1057 Lessons from the Inner-City Asthma Consortium (ICAC). J Allergy Clin Immunol Pract. 1058 2016;4(1):22-6. 1059 129. O'Connor GT, Lynch SV, Bloomberg GR, Kattan M, Wood RA, Gergen PJ, et al. Early-1060 life home environment and risk of asthma among inner-city children. J Allergy Clin 1061 Immunol. 2018;141(4):1468-75. 1062 130. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic 1063 reference values for spirometry for the 3-95-yr age range: the global lung function 2012 1064 equations. Eur Respir J. 2012;40(6):1324-43. 1065 131. Bernert JT, Harmon TL, Sosnoff CS, McGuffey JE. Use of continine immunoassay test 1066 strips for preclassifying urine samples from smokers and nonsmokers prior to analysis by 1067 LC-MS-MS. J Anal Toxicol. 2005;29(8):814-8. 1068 132. Regier AA, Farjoun Y, Larson DE, Krasheninina O, Kang HM, Howrigan DP, et al. 1069 Functional equivalence of genome sequencing analysis pipelines enables harmonized 1070 variant calling across human genetics projects. Nat Commun. 2018;9(1):4038. 1071 133. Kowalski MH, Qian H, Hou Z, Rosen JD, Tapia AL, Shan Y, et al. Use of >100,000 1072 NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium whole genome sequences improves imputation quality and detection of rare variant associations in 1073 1074 admixed African and Hispanic/Latino populations. PLoS Genet. 2019;15(12):e1008500. 1075 134. Zhang F, Flickinger M, Taliun SAG, In PPGC, Abecasis GR, Scott LJ, et al. Ancestry-1076 agnostic estimation of DNA sample contamination from sequence reads. Genome Res. 1077 2020;30(2):185-94. 1078 135. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation 1079 PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7. 1080 136. McKennan C, Naughton K, Stanhope C, Kattan M, O'Connor GT, Sandel MT, et al. 1081 Longitudinal data reveal strong genetic and weak non-genetic components of ethnicity-1082 dependent blood DNA methylation levels. Epigenetics. 2020. doi: 1083 10.1080/15592294.2020.1817290:1-15. 1084 137. Jun G, Flickinger M, Hetrick KN, Romm JM, Doheny KF, Abecasis GR, et al. Detecting 1085 and estimating contamination of human DNA samples in sequencing and array-based 1086 genotype data. Am J Hum Genet. 2012;91(5):839-48.

- 1087 138. Hao W, Storey JD. Extending Tests of Hardy-Weinberg Equilibrium to Structured
 1088 Populations. Genetics. 2019;213(3):759-70.
- 1089 139. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, et al. The variant
 call format and VCFtools. Bioinformatics. 2011;27(15):2156-8.
- 1091 140. Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of
 SAMtools and BCFtools. Gigascience. 2021;10(2).
- 1093 141. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A
 1094 global reference for human genetic variation. Nature. 2015;526(7571):68-74.
- 1095 142. Bergstrom A, McCarthy SA, Hui R, Almarri MA, Ayub Q, Danecek P, et al. Insights into
 1096 human genetic variation and population history from 929 diverse genomes. Science.
 1097 2020;367(6484).
- 1098 143. Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in 1099 unrelated individuals. Genome Res. 2009;19(9):1655-64.
- 1100 144. Conomos MP, Miller MB, Thornton TA. Robust inference of population structure for
 ancestry prediction and correction of stratification in the presence of relatedness. Genet
 Epidemiol. 2015;39(4):276-93.
- 1103 145. Conomos MP, Reiner AP, Weir BS, Thornton TA. Model-free Estimation of Recent
 1104 Genetic Relatedness. Am J Hum Genet. 2016;98(1):127-48.
- 146. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship
 inference in genome-wide association studies. Bioinformatics. 2010;26(22):2867-73.
- 1107 147. Shringarpure SS, Bustamante CD, Lange K, Alexander DH. Efficient analysis of large
 1108 datasets and sex bias with ADMIXTURE. BMC Bioinformatics. 2016;17:218.
- 148. Sofer T, Zheng X, Gogarten SM, Laurie CA, Grinde K, Shaffer JR, et al. A fully adjusted
 two-stage procedure for rank-normalization in genetic association studies. Genet
 Epidemiol. 2019;43(3):263-75.
- 1112 149. McCaw ZR, Lane JM, Saxena R, Redline S, Lin X. Operating characteristics of the rank1113 based inverse normal transformation for quantitative trait analysis in genome-wide
 1114 association studies. Biometrics. 2020;76(4):1262-72.
- 1115 150. Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to variable selection
 in regression, with application to genetic fine mapping. Journal of the Royal Statistical
 Society: Series B (Statistical Methodology). 2020;82(5):1273-300.
- 1118 151. Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations.
 1119 Bioinformatics. 2012;28(10):1353-8.

- 1120 152. McKennan C, Nicolae D. Accounting for unobserved covariates with varying degrees of
 1121 estimability in high-dimensional biological data. Biometrika. 2019;106(4):823-40.
- 1122 153. Zhang D. A Coefficient of Determination for Generalized Linear Models. The American
 1123 Statistician. 2017;71(4):310-6.
- 1124 154. Fox J, Kleiber C, Zeileis A. ivreg: Two-Stage Least-Squares Regression with Diagnostics.
 https://john-d-fox.github.io/ivreg/2021.
- 1126 155. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for
 1127 Mendelian randomization. Stat Methods Med Res. 2017;26(5):2333-55.
- 1128 156. Burgess S, Thompson SG. Use of allele scores as instrumental variables for Mendelian
 1129 randomization. International Journal of Epidemiology. 2013;42(4):1134-44.
- 1130 157. Alfons A, Ateş NY, Groenen PJF. A Robust Bootstrap Test for Mediation Analysis.
 1131 Organizational Research Methods.0(0):1094428121999096.
- 1132 158. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast
 1133 universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.
- 1134 159. Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model
 1135 analysis tools for RNA-seq read counts. Genome Biol. 2014;15(2):R29.
- 1136 160. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
 expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res.
 2015;43(7):e47.
- 1139 161. Jager R, Migliorini G, Henrion M, Kandaswamy R, Speedy HE, Heindl A, et al. Capture
 1140 Hi-C identifies the chromatin interactome of colorectal cancer risk loci. Nat Commun.
 1141 2015;6:6178.
- 1142 162. Mifsud B, Tavares-Cadete F, Young AN, Sugar R, Schoenfelder S, Ferreira L, et al.
 1143 Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C.
 1144 Nat Genet. 2015;47(6):598-606.
- 1145 163. Montefiori LE, Sobreira DR, Sakabe NJ, Aneas I, Joslin AC, Hansen GT, et al. A promoter
 1146 interaction map for cardiovascular disease genetics. Elife. 2018;7.
- 1147 164. Cairns J, Freire-Pritchett P, Wingett SW, Varnai C, Dimond A, Plagnol V, et al.
 1148 CHiCAGO: robust detection of DNA looping interactions in Capture Hi-C data. Genome
 1149 Biol. 2016;17(1):127.
- 1150

1151 SUPPORTING INFORMATION

1152

1153 S1 Fig. Whole-genome sequencing depth and coverage. A) Histogram of 1,035 whole-1154 genome sequencing (WGS) samples from APIC and URECA by mean depth of coverage. B) 1155 Histogram of WGS samples based on proportion of genome covered at 20x, 25x, and 30x 1156 depth. APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and 1157 Childhood Asthma study. 1158 1159 1160 S1 Table. Post-QC sequencing call concordance between replicates. Variant call 1161 concordance between three pairs of replicate samples, by variant type and cohort allele 1162 frequency. SNPs, single nucleotide polymorphisms; MAF, minor allele frequency; InDels, 1163 insertions and deletions. 1164 1165 S2 Table. FEV₁-associated variants in chr14q32.33. All variants in chr14q32.33 associated 1166 with FEV₁ (% predicted) with $p<1x10^{-5}$ (n=82) in GWAS of 896 participants from APIC & 1167 URECA. N, number of genotyped individuals. MAF, minor allele frequency; 95% CI, 95% 1168 1169 confidence interval; SE, standard error; P, P-value (Wald); FEV₁, forced expiratory volume in 1170 one second; APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment 1171 and Childhood Asthma study. 1172 1173

S2 Fig. Distribution of lung function measures by study. A) Distribution of FEV₁ (%
predicted) in APIC and URECA. B) Distribution of FEV₁/FVC in APIC and URECA. APIC,
Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma
study. FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.

1178 1179

S3 Fig. P-value distributions of GWAS results. Quantile-quantile plots of the GWAS results
with corresponding genomic control factors (lambda) are shown for A) FEV₁ (% predicted) and
B) FEV₁/FVC. FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.

1184

S4 Fig. Fine-mapping results for FEV₁ (% predicted) at the *TDRD9* locus. The X-axis shows the chromosome position on chromosome 14. The Y-axis is the posterior inclusion probability (PIP). Variants highlighted in red represent a credible set, in which there is a 95% probability that at least one of the variants is causal. FEV₁, forced expiratory volume in one second.

1190

1191 **S5 Fig. Genome-wide association results without adjustment for asthma.** GWAS

1192 Manhattan plots for **A**) FEV_1 and **B**) FEV_1/FVC ratio, without adjustment for asthma status. The

1193 horizontal red line indicates genome-wide significance ($p \le 2.5 \times 10^{-8}$). The dotted horizontal blue

1194 line indicates $p=1x10^{-5}$. Variants colored in grey are the GWAS results with asthma adjustment. 1195 FEV₁, forced expiratory volume in one second; FEV₁/FVC, ratio of FEV₁ to forced vital capacity. 1196

- S6 Fig. Replication of FEV₁ GWAS SNPs. Association statistics for previously identified FEV₁
 GWAS SNPs [23]. 64 out of 70 previously identified SNPs were genotyped in APIC & URECA.
 GWAS, genome-wide association study; SNP, single nucleotide polymorphism; APIC, Asthma
 Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study.
 FEV₁, forced expiratory volume in one second.
- 1203 1204

1197

S7 Fig. Replication of FEV₁/FVC GWAS SNPs. Association statistics for previously identified
 FEV₁/FVC GWAS SNPs [23]. 112 out of 117 previously identified SNPs were genotyped in
 APIC & URECA. GWAS, genome-wide association study; SNP, single nucleotide
 polymorphism; APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment
 and Childhood Asthma study. FEV₁, forced expiratory volume in one second; FVC, forced vital
 capacity.

- 1211
- 1212

S3 Table. MeQTL analysis results and associations with FEV₁. All CpG sites where DNA
methylation levels in NECs at age 11 in URECA were associated with rs10220464 at FDR<0.05
are shown with their corresponding associations with FEV₁. The FDR-adjusted P-values (FDR
Q) correspond to a 5% false-discovery rate. FDR, false discovery rate; 95% CI, 95% confidence
interval; FEV₁, forced expiratory volume in one second; URECA, Urban Environment and
Childhood Asthma study.

1219

1220

S8 Fig. NicAlert Results by Study. Distribution of urine cotinine levels, as measured using
NicAlert immunochromatographic assays, which report results on a scale of 0-6 according to the
labeled concentration ranges. Proportions were calculated relative to the number of samples
with available NicAlert results. APIC, Asthma Phenotypes in the Inner City study; URECA,
Urban Environment and Childhood Asthma study.

1226 1227

S9 Fig. DNA methylation at cg03306306 by smoking exposure. DNA methylation levels at cg03306306 are shown by rs10220464 genotype in URECA participants with low and high smoking exposures in (**A**) NECs at age 11 and (**B**) PBMCs at age 7. FEV₁ (% predicted) are also shown by cg03306306 DNA methylation levels in URECA participants with low and high smoking exposures in (**C**) NECs at age 11 and (**D**) PBMCs at age 7. NECs, nasal epithelial cells; PBMCs, peripheral blood mononuclear cells; FEV₁, forced expiratory volume in one second; URECA, Urban Environment and Childhood Asthma study.

- 1235
- 1236

S10 Fig. Genotype associations with FEV₁ by smoking exposure. FEV₁ (% predicted) are
shown by rs10220464 genotype in APIC & URECA participants with low and high smoking
exposures according to urine cotinine levels. FEV₁, forced expiratory volume in one second;
APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood
Asthma study.

1242 1243

S4 Table. rs10220464 eQTL analysis results. Results of eQTL analyses in NECs and PBMCs
with rs10220464 for all genes within 1 Mb in URECA. Gene expression was measured in counts
per million mapped reads. The FDR-adjusted P-values (FDR Q) correspond to a 5% falsediscovery rate. FDR, false discovery rate; 95% CI, 95% confidence interval; NECs, nasal
epithelial cells; PBMCs, peripheral blood mononuclear cells; URECA, Urban Environment and
Childhood Asthma study.

1250 1251

S11 Fig. *PPP1R13B* expression in NECs vs. smoking exposure, FEV₁. *PPP1R13B*expression in NECs at age 11 was not associated with smoking exposure at age 10 (A) nor with
FEV₁ (% predicted) at age 10 (B) in URECA. NECs, nasal epithelial cells; FEV₁, forced
expiratory volume in one second; URECA, Urban Environment and Childhood Asthma.

1258S5 Table. Chromatin interactions with FEV1-associated SNPs. Bait and target fragments1259refer to mapped Hi-C restriction fragments on chr14 (hg38) for gene promoters and putative1260enhancers, respectively. FEV1 SNPs refer to number of FEV1-associated variants ($p<1x10^{-5}$)1261within 1kb of target fragment. SNPs, single nucleotide polymorphisms; FEV1, forced expiratory1262volume in one second.

1263 1264

1257

S6 Table. Age at used lung function measure in URECA. URECA, Urban Environment and
 Childhood Asthma study; FEV₁, forced expiratory volume in one second; FVC, forced vital
 capacity.

1268 1269

S7 Table. Study samples. APIC, Asthma Phenotypes in the Inner City study; URECA, Urban
 Environment and Childhood Asthma study; WGS, whole-genome sequencing; NECs, nasal
 epithelial cells; PBMCs, peripheral blood mononuclear cells.

1273 1274

1275 S12 Fig. Data availability across APIC and URECA. Data availability for measures used in 1276 this study are shown for all sequenced samples. Each row represents a pattern of available and 1277 missing data, with green squares indicating available data and grey squares indicating missing 1278 data. Total counts of available data points for each variable are listed across the top of the 1279 figure. Total counts for each data availability pattern are listed along the right.

- 1280

1282 **S13 Fig. Transitions/transversions vs. quality/depth in WGS variant calls.** The

transition/transversion ratio (TS/TV) is plotted against the variant call quality/depth metric (QD)
 across all WGS SNP calls in APIC & URECA. Sites with QD less than 4 or greater than 34 were
 removed from consideration in this study. SNPs, single nucleotide polymorphisms; WGS, whole genome sequencing; APIC, Asthma Phenotypes in the Inner City study; URECA, Urban
 Environment and Childhood Asthma study.

1288 1289

1290 S14 Fig. Intercorrelation of Mendelian randomization candidate instrument SNPs in

URECA. Instrumental variables were chosen from a set of candidate SNPs that were at least
 nominally associated with cg03306306 methylation with p<0.15. The correlation values between
 these SNPs are shown, clustered using Ward's method. The four SNPs used for the instrument
 are highlighted. URECA, Urban Environment and Childhood Asthma.

- 1295
- 1296

1297 S8 Table. Additional phenotypic, socioeconomic, and environmental data. Additional

variables examined for potential confounding in mediation analyses for APIC & URECA. APIC,
Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma
study.

1301 1302

1303 **S15 Fig. Intercorrelation of phenotypes and environmental variables in APIC & URECA.**

1304 The correlations are shown between FEV₁ (% predicted), smoking exposure (NicAlert), the

primary the lead FEV₁ SNP rs10220464, DNA methylation at cg03306306, 11 environmental

1306 exposures, and 2 socioeconomic indicators, clustered using Ward's method. APIC, Asthma

1307 Phenotypes in the Inner City study; exp., exposure; URECA, Urban Environment and Childhood

1308 Asthma.











Cohort	rs10220464 vs. FEV ₁	Ν	MAF	β _z [95% Cl]	Р
All	◆ -	896	0.295	-0.31 [-0.410.21]	2.42×10 ⁻⁹
Black (non-Hispanic)		606	0.275	-0.27 [-0.400.15]	1.88×10⁻⁵
Hispanic	⊢-◆1	224	0.331	-0.34 [-0.530.15]	7.15×10 ⁻⁴
White (non-Hispanic)	→ 1	9	0.464	-0.68 [-1.72- 0.37]	4.26×10 ⁻¹
APIC	⊢◆⊣	504	0.331	-0.30 [-0.430.16]	2.23×10⁻⁵
URECA	⊢◆-1	392	0.260	-0.23 [-0.370.09]	1.46×10⁻₃
Asthmatic	⊢♠⊣	677	0.305	-0.31 [-0.430.20]	1.62×10 ⁻⁷
Non-asthmatic		219	0.275	-0.23 [-0.410.05]	1.38×10 ⁻²
- -1.	ι ι ι 5 -1 -0.5 Ο Ο. β _z	5			







DNA Methylation: cg03306306

PBMCs





DNA Methylation: cg03306306









Variant Type	Variants (mean)	Call concordance
All Variants	4,284,228	0.9985
SNPs	3,793,694	0.9997
Common SNPs (MAF > 0.05)	3,244,661	0.9997
Low Frequency SNPs (0.01 > MAF ≤ 0.05)	383,918	0.9995
Rare SNPs (MAF ≤0.01)	165,115	0.9995
InDels	490,534	0.9892
Common InDels (MAF > 0.05)	428,621	0.9896
Low Frequency InDels $(0.01 > MAF \le 0.05)$	39,572	0.9845
Rare InDels (MAF ≤0.01)	22,340	0.9911

S1 Table. Post-QC sequencing call concordance between replicates.

Variant call concordance between three pairs of replicate samples, by variant type and cohort allele frequency. SNPs, single nucleotide polymorphisms; MAF, minor allele frequency; InDels, insertions and deletions.

S2 Table. FEV1-associated variants in chr14q32.33

Pos	rsID	Ν	Ref	Alt	MAF	Beta	SE	Р	Туре	Gene
103936818	rs10220464	896	Α	G	0.30	-0.311	0.052	2.42 x10 ⁻⁹	intronic	TDRD9
103926863	rs11850186	896	G	А	0.29	-0.307	0.052	5.34 x10 ⁻⁹	intergenic	ATP5MPL; TDRD9
103934654	rs4906387	896	С	Т	0.29	-0.305	0.052	6.20 x10 ⁻⁹	intronic	TDRD9
103935736	rs9285602	896	С	Т	0.29	-0.305	0.052	6.20 x10 ⁻⁹	intronic	TDRD9
103937635	rs9324069	896	G	А	0.29	-0.305	0.052	6.20 x10 ⁻⁹	intronic	TDRD9
103942966		896	GA	G	0.29	-0.305	0.052	6.20 x10 ⁻⁹	intronic	TDRD9
103960917	rs4900604	896	G	А	0.29	-0.305	0.052	6.20 x10 ⁻⁹	intronic	TDRD9
103963565	rs28574832	896	G	Т	0.29	-0.305	0.052	6.20 x10 ⁻⁹	intronic	TDRD9
103967867	rs4900605	896	G	Т	0.29	-0.305	0.052	6.20 x10 ⁻⁹	intronic	TDRD9
103997188	rs72712900	896	G	Α	0.29	-0.304	0.052	6.51 x10 ⁻⁹	intronic	TDRD9
103984806	rs11847797	896	G	А	0.29	-0.303	0.052	7.73 x10 ⁻⁹	intronic	TDRD9
103980079	rs58289480	896	А	G	0.29	-0.303	0.052	8.28 x10 ⁻⁹	intronic	TDRD9
103985095	rs4906396	896	А	С	0.29	-0.303	0.052	8.28 x10 ⁻⁹	intronic	TDRD9
103953683	rs72712884	896	С	G	0.29	-0.303	0.052	8.28 x10 ⁻⁹	intronic	TDRD9
104046654	rs143594477	896	С	СТ	0.29	-0.302	0.052	9.12 x10 ⁻⁹	intronic	TDRD9
104028226	rs10137997	896	Т	С	0.29	-0.301	0.052	9.73 x10 ⁻⁹	intronic	TDRD9
104034493	rs9944163	896	G	Т	0.29	-0.301	0.052	9.73 x10 ⁻⁹	intronic	TDRD9
104069368	rs72714937	896	С	Т	0.29	-0.302	0.052	9.80 x10 ⁻⁹	intergenic	TDRD9; ASPG
104059833	rs11160785	896	т	А	0.29	-0.300	0.052	1.03 x10 ⁻⁸	intergenic	TDRD9; ASPG
103934222	rs28461376	896	А	G	0.29	-0.301	0.052	1.06 x10 ⁻⁸	intronic	TDRD9
103963484		896	TC	Т	0.29	-0.301	0.052	1.06 x10 ⁻⁸	intronic	TDRD9
104037291	rs4906408	896	G	Т	0.29	-0.299	0.052	1.14 x10 ⁻⁸	intronic	TDRD9
104030861	rs10135338	896	G	Α	0.29	-0.299	0.052	1.18 x10 ⁻⁸	intronic	TDRD9
104035861	rs10134394	896	G	Α	0.29	-0.299	0.052	1.18 x10 ⁻⁸	intronic	TDRD9
104036696	rs11160780	896	G	А	0.29	-0.299	0.052	1.18 x10 ⁻⁸	intronic	TDRD9
104037342	rs4900608	896	G	Α	0.29	-0.299	0.052	1.18 x10⁻ ⁸	intronic	TDRD9
104038178	rs4906409	896	Т	С	0.29	-0.299	0.052	1.18 x10⁻ ⁸	intronic	TDRD9
104039412	rs10144682	896	G	Α	0.29	-0.299	0.052	1.18 x10 ⁻⁸	intronic	TDRD9
104012687	rs11851441	896	Α	G	0.29	-0.299	0.052	1.23 x10 ⁻⁸	intronic	TDRD9
104031206	rs10135507	896	С	Т	0.29	-0.298	0.052	1.25 x10 ⁻⁸	exonic	TDRD9
103998027	rs55938939	896	G	Α	0.29	-0.299	0.052	1.26 x10 ⁻⁸	intronic	TDRD9
104048481	rs61244535	896	С	G	0.29	-0.299	0.052	1.29 x10 ⁻⁸	intronic	TDRD9
104051127	rs28644198	896	С	Α	0.29	-0.299	0.052	1.29 x10⁻ ⁸	intronic	TDRD9
104054541	rs28377615	896	G	Α	0.29	-0.299	0.052	1.29 x10 ⁻⁸	intergenic	TDRD9; ASPG
103997438	rs4906397	896	С	Т	0.29	-0.298	0.052	1.31 x10 ⁻⁸	intronic	TDRD9
103999081	rs4906399	896	С	Т	0.29	-0.298	0.052	1.31 x10 ⁻⁸	intronic	TDRD9
104005628	rs12147936	896	С	Т	0.29	-0.298	0.052	1.31 x10 ⁻⁸	intronic	TDRD9
104010259	rs145867870	896	С	СТ	0.29	-0.298	0.052	1.31 x10 ⁻⁸	intronic	TDRD9
104013496	rs11851723	896	С	Т	0.29	-0.298	0.052	1.31 x10 ⁻⁸	intronic	TDRD9
104014746	rs11160779	896	Т	С	0.29	-0.298	0.052	1.31 x10 ⁻⁸	exonic	TDRD9
104016537	rs72714909	896	С	A	0.29	-0.298	0.052	1.31 x10 ⁻⁸	intronic	TDRD9
103986068	rs10143030	896	С	G	0.29	-0.300	0.052	1.41 x10 ⁻⁸	intronic	TDRD9
103986303	rs10143389	896	G	A	0.29	-0.300	0.052	1.41 x10 ⁻⁸	exonic	TDRD9
103986825	rs61248168	896	Т	A	0.29	-0.300	0.052	1.41 x10 ⁻⁸	intronic	TDRD9
103990858	rs1957518	896	G	A	0.29	-0.300	0.052	1.41 x10 ⁻⁸	intronic	TDRD9
104072329	rs111576189	896	G	Α	0.29	-0.298	0.052	1.54 x10 ⁻⁸	intergenic	TDRD9; ASPG
104011541	rs28522352	896	Т	А	0.29	-0.296	0.052	1.79 x10⁻ ⁸	intronic	TDRD9
104003975	rs8010286	896	Т	С	0.29	-0.293	0.052	2.06 x10 ⁻⁸	intronic	TDRD9
104004349	rs28391043	896	G	Α	0.29	-0.294	0.052	2.22 x10 ⁻⁸	intronic	TDRD9
104027784	rs28725314	896	С	Т	0.29	-0.290	0.052	2.96 x10 ⁻⁸	intronic	TDRD9
103970594	rs11851097	896	С	Т	0.36	-0.267	0.048	3.28 x10 ⁻⁸	exonic	TDRD9

Pos	rsID	Ν	Ref	Alt	MAF	Beta	SE	Р	Туре	Gene
103987132	rs200735321	880	Α	G	0.26	-0.311	0.057	6.98 x10⁻ ⁸	intronic	TDRD9
104067149	rs10782497	896	т	С	0.39	-0.265	0.049	1.08 x10 ⁻⁷	intergenic	TDRD9; ASPG
104019632	rs74089113	896	G	С	0.44	-0.246	0.046	1.25 x10 ⁻⁷	intronic	TDRD9
104071795	rs35775205	896	А	G	0.37	-0.264	0.050	1.72 x10 ⁻⁷	intergenic	TDRD9; ASPG
104038358	rs877009	896	Т	С	0.43	-0.240	0.046	3.06 x10 ⁻⁷	intronic	TDRD9
104007407	rs12100528	896	G	Α	0.43	-0.240	0.047	3.32 x10 ⁻⁷	intronic	TDRD9
104016337	rs7158223	896	G	Т	0.42	-0.238	0.046	3.83 x10 ⁻⁷	intronic	TDRD9
103947548	rs7144813	896	G	С	0.35	-0.244	0.049	8.48 x10 ⁻⁷	intronic	TDRD9
103937851	rs10141985	896	G	Α	0.34	-0.242	0.050	1.53 x10⁻ ⁶	intronic	TDRD9
103939314	rs7148877	896	А	G	0.34	-0.241	0.050	1.73 x10⁻ ⁶	intronic	TDRD9
103945800	rs12147460	896	Т	G	0.34	-0.241	0.050	1.73 x10⁻ ⁶	intronic	TDRD9
104032500	rs9944058	896	С	Т	0.42	-0.235	0.049	2.22 x10⁻ ⁶	intronic	TDRD9
103981884	rs4906395	896	Т	С	0.42	-0.220	0.047	2.71 x10 ⁻⁶	intronic	TDRD9
103958246	rs10149734	896	А	С	0.41	-0.221	0.047	3.04 x10 ⁻⁶	intronic	TDRD9
103962412	rs72712889	896	Т	С	0.41	-0.221	0.047	3.04 x10 ⁻⁶	intronic	TDRD9
103967964	rs4906392	896	Т	С	0.41	-0.221	0.047	3.04 x10 ⁻⁶	intronic	TDRD9
103995217	rs10132153	896	С	А	0.41	-0.220	0.047	3.16 x10⁻ ⁶	intronic	TDRD9
104036896	rs7156122	896	G	А	0.41	-0.217	0.046	3.28 x10 ⁻⁶	intronic	TDRD9
104014863	rs397949797	896	Α	AT	0.41	-0.216	0.046	3.75 x10⁻ ⁶	intronic	TDRD9
103979872	rs8022833	896	А	G	0.41	-0.219	0.047	3.87 x10⁻ ⁶	intronic	TDRD9
103981060	rs1957517	896	Α	G	0.41	-0.219	0.047	3.87 x10⁻ ⁶	intronic	TDRD9
103995157	rs10132127	896	С	G	0.41	-0.218	0.047	4.02 x10 ⁻⁶	intronic	TDRD9
104004783	rs9671921	896	А	G	0.49	-0.214	0.046	4.98 x10 ⁻⁶	intronic	TDRD9
104008697	rs4906401	896	А	G	0.41	-0.215	0.047	5.23 x10 ⁻⁶	intronic	TDRD9
104001342	rs61319604	896	С	Т	0.41	-0.215	0.047	5.35 x10⁻ ⁶	intronic	TDRD9
104002208	rs72714904	896	Т	С	0.41	-0.215	0.047	5.35 x10⁻ ⁶	intronic	TDRD9
104003206	rs10135296	896	G	Т	0.41	-0.215	0.047	5.35 x10⁻ ⁶	intronic	TDRD9
104006916	rs4900607	896	А	G	0.49	-0.212	0.046	5.90 x10 ⁻⁶	intronic	TDRD9
104010388	rs4906402	896	G	А	0.41	-0.213	0.047	6.22 x10 ⁻⁶	intronic	TDRD9
104000834	rs7160557	896	G	А	0.48	-0.207	0.046	8.97 x10⁻ ⁶	intronic	TDRD9
104078948	rs4906415	896	G	А	0.19	-0.268	0.060	9.00 x10 ⁻⁶	intergenic	TDRD9; ASPG

All variants in chr14q32.33 associated with FEV₁ (% predicted) with p<1x10⁻⁵ (n=82) in GWAS of 896 participants from APIC & URECA. N, number of genotyped individuals. MAF, minor allele frequency; 95% CI, 95% confidence interval; SE, standard error; P, P-value (Wald); FEV₁, forced expiratory volume in one second; APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study.

CpG Site	Position (strand),	rs102	220464	FEV ₁		
•	ng38 (cnr14)	Beta [95% CI]	Р	FDR Q	Beta [95% Cl]	Р
cg21567958	103909862 (-)	0.10 [0.05, 0.14]	1.79 x10⁻⁵	0.01	-1.5 [-8.8, 5.7]	0.68
cg12183467	103885907 (-)	0.10 [0.05, 0.14]	1.31 x10 ⁻⁴	0.04	5.3 [-1.5, 12.1]	0.13
cg16820107	103970549 (-)	0.08 [0.04, 0.12]	1.62 x10 ⁻⁴	0.04	-5.4 [-13.4, 2.5]	0.18
cg03306306	104001397 (+)	0.07 [0.03, 0.11]	2.28 x10 ⁻⁴	0.04	-11.5 [-20.3, -2.7]	0.01
cg17298714	103938355 (+)	0.14 [0.07, 0.21]	2.36x10 ⁻⁴	0.04	-4.1 [-8.7, 0.4]	0.07

S3 Table. MeQTL analysis results and associations with FEV1

All CpG sites where DNA methylation levels in NECs at age 11 in URECA were associated with rs10220464 at FDR<0.05 are shown with their corresponding associations with FEV₁. The FDR-adjusted P-values (FDR Q) correspond to a 5% false-discovery rate. FDR, false discovery rate; 95% CI, 95% confidence interval; FEV₁, forced expiratory volume in one second; URECA, Urban Environment and Childhood Asthma study.

Gene		NECs	PBMCs		
	Beta [95% CI]	Р	FDR Q	Beta [95% CI]	Р
PPP1R13B	0.12 [0.06, 0.17]	1.26 x10⁻⁵	2.77 x10 ⁻⁴	0.01 [-0.08, 0.09]	0.87
BAG5	-0.06 [-0.02, -0.10]	0.0054	0.059	0.03 [-0.03, 0.08]	0.31
ASPG	0.12 [-0.02, 0.26]	0.089	0.48	NOT EXPRESSE	D
СКВ	-0.04 [0.01, -0.09]	0.10	0.48	0.13 [-0.03, 0.30]	0.12
KLC1	-0.04 [0.01, -0.08]	0.12	0.48	0.02 [-0.04, 0.07]	0.53
TNFAIP2	-0.05 [0.02, -0.12]	0.15	0.48	-0.11 [0.06, -0.28]	0.22
MARK3	-0.03 [0.01, -0.07]	0.15	0.48	-0.02 [0.02, -0.06]	0.40
C14orf2	0.01 [-0.01, 0.03]	0.23	0.61	-0.03 [0.03, -0.09]	0.35
XRCC3	0.08 [-0.06, 0.22]	0.25	0.61	0.00 [0.06, -0.07]	0.92
ZFYVE21	0.02 [-0.01, 0.04]	0.28	0.61	-0.02 [0.03, -0.07]	0.49
ADSSL1	0.04 [-0.04, 0.11]	0.33	0.61	0.04 [-0.09, 0.17]	0.54
PLD4	0.07 [-0.07, 0.20]	0.33	0.61	0.07 [-0.12, 0.26]	0.47
SIVA1	-0.01 [0.01, -0.03]	0.36	0.61	0.01 [-0.06, 0.09]	0.77
EXOC3L4	-0.08 [0.14, -0.29]	0.47	0.69	NOT EXPRESSE	D
TRMT61A	-0.02 [0.04, -0.09]	0.48	0.69	-0.04 [0.04, -0.12]	0.32
CEP170B	-0.02 [0.05, -0.09]	0.51	0.69	0.02 [-0.11, 0.14]	0.78
APOPT1	-0.02 [0.04, -0.08]	0.56	0.69	-0.03 [0.03, -0.09]	0.37
EIF5	-0.01 [0.02, -0.04]	0.60	0.69	-0.03 [0.05, -0.12]	0.44
TDRD9	-0.07 [0.21, -0.36]	0.60	0.69	0.01 [-0.23, 0.26]	0.91
ZBTB42	-0.02 [0.05, -0.08]	0.63	0.69	-0.09 [0.01, -0.19]	0.089
INF2	-0.01 [0.08, -0.10]	0.84	0.85	0.04 [-0.06, 0.13]	0.45
AKT1	0.00 [0.03, -0.03]	0.85	0.85	-0.02 [0.04, -0.08]	0.57
AL049840.1	NOT E	XPRESSED		0.00 [0.08, -0.09]	0.93
AL049840.4	NOT E	XPRESSED		0.01 [-0.05, 0.08]	0.65
AL049840.5	NOT E	XPRESSED		0.02 [-0.08, 0.13]	0.68
AL133367.1	NOT E	XPRESSED		0.09 [-0.02, 0.20]	0.12
LINC00638	NOT E	XPRESSED		0.03 [-0.11, 0.18]	0.66

S4 Table. rs10220464 eQTL analysis results

Results of eQTL analyses in NECs and PBMCs with rs10220464 for all genes within 1 Mb in URECA. Gene expression was measured in counts per million mapped reads. The FDR-adjusted P-values (FDR Q) correspond to a 5% false-discovery rate. FDR, false discovery rate; 95% CI, 95% confidence interval; NECs, nasal epithelial cells; PBMCs, peripheral blood mononuclear cells; URECA, Urban Environment and Childhood Asthma study.

Promoter	Bait Fragment	Target Fragment	Strand	Distance	FEV ₁ SNPs	CHiCAGO Score
PPP1R13B	103845355-103845955	104003512-104004312	-	157557	4	9.38
CDCA4	105020395-105021827	104010864-104011532	-	1008863	3	7.65
PPP1R13B	103845355-103845955	104004616-104004922	-	158661	4	7.16
ZFYVE21	103716777-103717467	103948470-103949743	+	231003	1	6.57
ZFYVE21	103716777-103717467	103933835-103934479	+	216368	2	6.49
C14orf79	104985639-104987255	103935625-103936182	+	1049457	3	6.10
MARK3	103385080-103385712	103937160-103938502	+	551448	4	5.89
ZFYVE21	103715624-103716777	103981359-103981909	+	264582	2	5.89
PLD4	104927266-104927937	103963380-103964018	+	963248	3	5.69
ZFYVE21	103715624-103716777	103933397-103933835	+	216620	2	5.62
ADSSL1	104720007-104724747	104017055-104017482	+	702525	2	5.52
APOPT1	103562490-103563614	103999031-103999343	+	435417	1	5.48
СКВ	103521551-103522109	103997308-103998030	-	475199	3	5.26
MARK3	103385881-103386341	103958731-103959336	+	572390	1	5.19
PPP1R13B	103845355-103845955	104036454-104037811	-	190499	7	5.00

S5 Table. Chromatin interactions with FEV1-associated SNPs

Bait and target fragments refer to mapped Hi-C restriction fragments on chr14 (hg38) for gene promoters and putative enhancers, respectively. FEV₁ SNPs refer to number of FEV₁-associated variants (p<1x10⁻⁵) within 1kb of target fragment. SNPs, single nucleotide polymorphisms; FEV₁, forced expiratory volume in one second.

Age	Count				
(years)	FEV ₁	FEV ₁ /FVC			
10	382	372			
9	26	30			
8	10	11			
7	8	5			
6	6	10			
5	9	10			

S6 Table. Age at used lung function measure in URECA

URECA, Urban Environment and Childhood Asthma study; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.

Cohort	Sample	Cell Type	Age Collected	N
APIC	WGS	-	-	508
URECA	WGS	-	-	527
URECA	DNA Methylation	NECs	11	286
URECA	DNA Methylation	PBMCs	7	169
URECA	RNA-Seq	NECs	11	324
URECA	RNA-Seq	PBMCs	2	132

S7 Table. Study samples

APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study; WGS, whole-genome sequencing; NECs, nasal epithelial cells; PBMCs, peripheral blood mononuclear cells.

Variable	Description	Units	Ν				
Socioeconomic factors							
Income<\$15K	Family yearly income <\$15,000	yes/no	1018				
Caretaker education	Caretaker completed high school	yes/no	1031				
Environmental expos	ures						
Gas stove at home	Gas stove in home	yes/no	982				
Dampness at home	Water problems in home	yes/no	981				
AC at home	AC unit in child's bedroom	yes/no	982				
Airvents at home	Forced air for heat in home	yes/no	983				
Rodent allergen exposure	Mus m 1 (mouse) bedroom allergen levels	log(µg/g)	847				
Roach allergen exposure	Bla g 1 (German cockroach) bedroom allergen levels	log(µg/g)	850				
Dust mite allergen exposure	Combined Der f 1 (<i>Dermatophagoides farina</i>) and Der p 1 (<i>Dermatophagoides</i> <i>pteronyssinus</i>) bedroom allergen levels	log(µg/g)	756				
Dog allergen exposure	Can f 1 bedroom allergen levels	log(µg/g)	839				
Cat allergen exposure	Fel d 1 bedroom allergen levels	log(µg/g)	839				
NO ₂ at home	Indoor nitrogen dioxide levels	log(ppb)	900				
Caloric intake	Total caloric intake	log(calories/day)	787				

S8 Table. Additional phenotypic, socioeconomic, and environmental data

Additional variables examined for potential confounding in mediation analyses for APIC & URECA. APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study.









В







Expected $-\log_{10}(p)$

FEV ₁	
GWAS	SNP

Shrine et al.
APIC & URECA

GWAS SNPs	(Shrine et al.)	(APIC & URECA)
rs9610955	7×10 ⁻¹¹	1×10 ⁻⁰⁴
rs1722225	mber 4^{2} 2^{19} The co	pyright holder for this preprint
rs9807669/hich was not certified by peer review) is the author/funder, who has granted medRxi	v a licensecto3display	the preprint in perpetuity.
rs4651005	l license 1×10 ⁻¹³	1×10 ⁻²
rs9892893	2×10 ⁻¹³	9×10 ⁻²
rs79412431	3×10 ⁻⁴⁹	4×10 ⁻¹
rs559233	8×10 ⁻¹³	1×10 ⁻¹
rs6501455	1×10 ⁻³⁶	2×10 ⁻¹
rs879394	1×10 ⁻²⁵	2×10 ⁻¹
	3×10 ⁻¹⁰	3×10 ⁻¹
	2×10	0v10 ⁻¹
re230/13/0	1×10	2×10 3×10 ⁻¹
re1689510	6×10 ⁻¹⁰	5×10 ⁻¹
rs2304645	3×10 ⁻¹¹	4×10 ⁻¹
rs1513272	1×10 ⁻¹⁷	4×10 ⁻¹
rs6032942	4×10 ⁻¹⁰	5×10 ⁻¹
rs12096239	2×10 ⁻¹²	6×10 ⁻¹
rs4294980	4×10 ⁻¹⁰	5×10⁻¹
rs9947743 🗕 🛁	1×10 ⁻¹²	6×10⁻¹
rs11082051	4×10 ⁻⁰⁸	7×10 ⁻¹
rs28613267 —	9×10 ⁻¹³	6×10 ⁻¹
rs11085744 —	8×10 ⁻¹¹	7×10 ⁻¹
rs7424771	7×10 ⁻¹³	7×10 ⁻¹
rs7098573	3×10 ⁻²¹	7×10⁻¹
rs4132748	1×10 ⁻¹⁵	8×10⁻¹
rs4885681	2×10 ⁻¹²	8×10 ⁻¹
rs2701110	2×10 ⁻¹⁶	1×10 ⁰
rs11176001	5×10 ⁻¹⁷	1×10 ⁰
rs12331869	3×10 ⁻⁰⁹	9×10 ⁻¹
rs12811814	3×10 ⁻¹⁰	9×10 ⁻¹
rs6539952	4×10 ⁻¹⁰	9×10 ⁻¹
rs10850377	4×10 ⁻¹⁵	9×10 ⁻¹
	1×10 ¹¹	9×10 '
rs0445932	4×10 ⁻²⁰	8×10 ⁻¹
ro11052672	1×10 ⁻¹⁴	0X IU 8v10 ⁻¹
rs4796334	2×10 ⁻⁰⁹	8×10 ⁻¹
rs7041139	3×10 ⁻¹²	7×10 ⁻¹
rs8047194	7×10 ⁻¹⁹	7×10 ⁻¹
rs2974389	2×10 ⁻¹²	7×10 ⁻¹
rs4128298	4×10 ⁻¹¹	7×10 ⁻¹
rs2571445	7×10 ⁻³³	7×10⁻¹
rs7082066	2×10 ⁻¹³	6×10 ⁻¹
rs11191841	6×10 ⁻¹³	6×10 ⁻¹
rs12707691	2×10 ⁻¹⁶	6×10⁻¹
rs12737805	7×10 ⁻¹³	6×10 ⁻¹
rs113111175	1×10 ⁻⁹	8×10⁻¹
rs2627237	4×10 ⁻⁹	3×10⁻¹
rs2236180	1×10 ⁻¹²	6×10 ⁻¹
rs12446589	3×10 ⁻⁸	5×10 ⁻¹
rs1978968	9×10 ⁻²⁷	6×10 ⁻¹
rs4866846	3×10 ⁻¹⁷	3×10 ⁻¹
rs4968200	5×10 ⁻¹¹	3×10 ⁻¹
	9×10-10	3×10 ⁻¹
	4×10°*	JX IU ' 2v-10-1
	3×10 ⁻⁰⁹	∠×10 ⁻¹
re11730847	3×10 ⊿∿10 ⁻¹³	ا×۱∪ 5⊽10 ⁻¹
rs10838435	-+×10 2∨10 ⁻¹⁰	8×10 ⁻²
rs1102077	4∨10 ⁻¹⁵	2×10 ⁻¹
rs78101726	8×10 ⁻²⁵	1x10 ⁻¹
rs2894837	9×10 ⁻¹³	9×10 ⁻³
rs71490394	2×10 ⁻²⁷	2×10 ⁻²
		·····
-0.5 0 0.5		

β (95% CI)

FEV,/FVC GWAS SNPs	■ Shrine et al. ◆ APIC & URECA	P-value (Shrine et al.)	P-value (APIC & URECA)
rs17280293		2×10 ⁻¹³¹	4×10 ⁻²
rs1192415	• • • • • • • • • • • • • • • • • • •	3×10 ⁻⁵ 2×10 ⁻⁴⁷	6×10 ⁻³
rs10059661		2×10 ⁻²²	5×10 ⁻²
rs2261360 rs8089099	·····	9×10 ⁻¹⁵ 2×10 ⁻¹⁸	3×10 ⁻² 3×10 ⁻²
rs13141641		3×10 ⁻¹⁸⁴	1×10 ⁻¹
rs2544536		4×10 ⁻²⁴	2×10 ⁻²
rs7970544 rs1529672		2×10 ⁻⁴⁰ 2×10 ⁻⁴¹	2×10 ⁻¹
rs541601		5×10 ⁻¹⁵	1×10 ⁻¹
rs35251997	· · · · · · · · · · · · · · · · · · ·	3×10 ⁻²⁷	5×10 ⁻¹
rs9970286	1/10.1101/2022.06.24.22276830: this version posted Nove	ember 4. 2022:16The cop	vright holder for this prepr
rs622017 which was not certified by p	eer review) is the author/funder, who has granted medRx	iv a license to display the	ne preprint in perpetuity.
rs11653958	It is made available under a CC-BY 4.0 Internationa	I license .9×10 ⁻¹³	4×10 ⁻¹
rs11648508		1×10 ⁻³⁸ 2×10 ⁻¹⁰	2×10 ⁻¹
rs755249		1×10 ⁻¹⁷	5×10 ⁻¹
rs2244592	→ B →	5×10 ⁻⁴²	3×10 ⁻¹
rs10919604		5×10 ⁻¹⁶	2×10 ⁻¹
rs1570203		6×10 ⁻²⁵	2×10 ⁻¹
rs985256	→	6×10 ⁻¹⁰	3×10 ⁻¹
rs56104880		5×10 ⁻¹⁵	3×10 ⁻¹
rs2009279 rs721917		2×10 ⁻¹⁵	3×10 ⁻¹
rs8082036		7×10 ⁻²⁴	4×10 ⁻¹
rs74053129		2×10 ⁻²²	7×10 ⁻¹
rs11134/66		8×10 ⁻⁰⁰ 4×10 ⁻²⁰	8×10 ⁻¹
rs1416685	·	6×10 ⁻¹⁷	4×10 ⁻¹
rs9661802		6×10 ⁻²³	4×10 ⁻¹
rs55884799 rs10983184		4×10 ⁻⁴⁰ 9×10 ⁻²⁸	5×10"' 4×10 ⁻¹
rs72673461		3×10 ⁻²⁰	7×10 ⁻¹
rs141942982		1×10 ⁻²⁰	5×10 ⁻¹
rs12202314		2×10 ⁻¹⁶	5×10 ⁻¹
rs72743974		4×10 ⁻¹³	6×10 ⁻¹
rs2283847		4×10 ⁻¹⁹	6×10 ⁻¹
rs4721457		2×10 ⁻¹³	7×10 ⁻¹
rs12470864		1×10	5×10 ⁻¹
rs7733410		2×10 ⁻⁹⁶	7×10 ⁻¹
rs2084448		5×10 ⁻¹⁴	7×10 ⁻¹
rs62012772 rs2869966		2×10 ⁻²⁰ 6×10 ⁻⁶⁶	9×10 ⁻¹
rs10836366	······	2×10 ⁻¹²	8×10 ⁻¹
rs2012453	·····•••••••••••••••••••••••••••••••••	4×10 ⁻²³	8×10 ⁻¹
rs996865		2×10 ⁻²⁵ 2×10 ⁻¹⁶	8×10 ⁻¹
rs10841302	······	2×10 ⁻¹²	9×10 ⁻¹
rs1491106		3×10 ⁻²³	9×10 ⁻¹
rs1951121		8×10 ⁻¹⁵	1×10 ⁰
rs12715478		1×10 ⁻²⁴	9×10 ⁻¹
rs1985511		6×10 ⁻¹²	9×10 ⁻¹
rs6533183		3×10 ⁻³²	8×10 ⁻¹
rs17666332		9×10 ⁻²⁴	9×10 ⁻¹
rs17531405	·	3×10 ⁻¹⁹	9×10 ⁻¹
rs193686		4×10 ⁻¹²	8×10 ⁻¹
rs75128958		2×10 ⁻²³	1×10 ⁰
rs330939	· · · · · · · · · · · · · · · · · · ·	5×10 ⁻²¹	8×10 ⁻¹
rs11858992	+ 	5×10 ⁻⁵⁵	8×10 ⁻¹
rs35246838	·····	1×10 ⁻²⁷ 4×10 ⁻²⁴	9×10 ⁻¹
rs62316310		2×10 ⁻²³	8×10 ⁻¹
rs62289340	······································	2×10 ⁻¹²	8×10 ⁻¹
rs4308141	······	4×10 ⁻⁰⁹ 5×10 ⁻¹³	9×10 ⁻¹
rs9634470		3×10 ⁻¹⁴	7×10 ⁻¹
rs79234094		3×10 ⁻²³	7×10 ⁻¹
rs35420030 ←		3×10 ⁻¹⁷	9×10 ⁻¹
rs586936		9×10 ⁻¹³	5×10 ⁻¹
rs4318980		9×10 ⁻¹³	5×10 ⁻¹
rs13206405		5×10 ⁻³¹	6×10 ⁻¹
rs10874851		3×10 ⁻¹³	5×10 ⁻¹
rs2999090		7×10 ⁻³²	6×10 ⁻¹
rs12522114		2×10 ⁻⁴¹	5×10 ⁻¹
rs1441358 rs70808473		4×10 ⁻¹⁴⁵ 2×10 ⁻³³	4×10 ⁻¹
rs12627254		7×10 ⁻²⁴	7×10 ⁻¹
rs2799098		5×10 ⁻²⁰	6×10 ⁻¹
rs13198081 rs113745635		3×10 ⁻³³	3×10 ⁻¹
rs1294417		2×10 ⁻¹ 4×10 ⁻³⁹	4×10 ⁻¹
rs4413223		1×10 ⁻¹³	3×10 ⁻¹
rs9661687		6×10 ⁻¹⁵	3×10 ⁻¹
rs55383987 ⊢ rs17163397		7×10 ⁻¹² 3×10 ⁻¹⁷	8×10 ⁻¹
rs1756281		1×10 ⁻¹⁹	2×10 ⁻¹
rs10059996	• • • • • • • • • • • • • • • • • • •	2×10 ⁻⁴²	2×10 ⁻¹
rs11234768		5×10 ⁻²⁰	5×10 ⁻¹
rs9636166		3×10 ⁻⁵⁴ 4×10 ⁻²³	2×10 ⁻ 3×10 ⁻¹
rs4309038		2×10 ⁻¹⁰	2×10 ⁻¹
rs62213732	• • • • • • • • • • • • • • • • • • •	9×10 ⁻²⁴	9×10 ⁻²
rs11134789 rs78442819		3×10 ⁻⁵⁹	7x10 ⁻²
rs34712979		∠×10 4×10 ⁻¹³⁴	3×10 ⁻¹
rs6435952		1×10 ⁻¹⁴	4×10 ⁻²
rs7090277		4×10 ⁻⁶⁷	2×10 ⁻²
rs11165787 rs987068		2×10 ⁻²¹ 2×10 ⁻³⁰	6x10 ^{°2} 1∨10 ⁻¹
		7×10 ⁻¹³	3×10 ⁻¹
rs12918140	······································		
rs12918140 rs11620380		5×10 ⁻¹²	2×10 ⁻¹

β (95% CI)

.



NECs

PBMCs








Cotinine concentration (ng/mL)

log₂(CPM)

P = 0.67

00

 \circ

ΟŌ

0

6.0

6.5

130	286	323	906	910	929	936	Available Missing
							1
							1
							1
							1
							1
							1
							1
							1
							2
							2
							2
							2
							2
							2
							3
							3
							3
							5
							ļ 6
							1 7
							9
							13
							13
							17
							1/
							22
							49
							/2
							87
							158
							529



PBMC Gene Expr.	DNA Methylation	NEC Gene Expr.	Asthma	NicAlert	FEV ₁ /FVC	FEV1	



QUAL / DEPTH

		г										-															Г			1		
										_				-															_	L		
	1.00	0.97	0.96	0.96	0.96	0.96	0.96	0.96	1.96	0.23	0.45	0.45	0.45	0.55	0.58	0.58	0.57	0.57	0.57	0.57	0.57	0.04	0.09	0.09	0.09	0.07	0.09	0.09	0.02	0.04	rs10220464	1
	0.97								0.99	0.23	0.45	0.44	0.45	0.54	0.60	0.60	0.59	0.59	0.59	0.59	0.59	0.04	0.09	0.09	0.09	0.07	0.09	0.09	0.01	0.03	rs72712900	
Γ	0.96								0.99	0.23	0.45	0.45	0.45	0.54	0.59	0.59	0.59	0.59	0.59	0.59	0.59	0.04	0.09	0.09	0.09	0.07	0.09	0.09	0.01	0.03	rs55938939	
	0.96								0.99	0.24	0.45	0.45	0.45	0.54	0.59	0.59	0.60	0.60	0.60	0.59	0.59	0.04	0.09	0.09	0.09	0.07	0.09	0.09	0.01	0.03	rs28391043	0.5
	0.96								1.00	0.24	0.46	0.46	0.46	0.55	0.60	0.60	0.61	0.61	0.61	0.60	0.60	0.04	0.10	0.09	0.09	0.07	0.09	0.09	0.01	0.03	rs145867870	
	0.96								1.00	0.24	0.45	0.45	0.45	0.55	0.59	0.60	0.60	0.60	0.60	0.60	0.60	0.04	0.10	0.09	0.09	0.07	0.09	0.09	0.01	0.03	rs8010286	
	0.96								1.00	0.24	0.46	0.45	0.46	0.55	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.04	0.10	0.09	0.09	0.07	0.09	0.09	0.01	0.03	rs12147936	0
	0.96								1.00	0.24	0.46	0.45	0.46	0.55	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.04	0.10	0.09	0.09	0.07	0.09	0.09	0.01	0.03	rs4906397	
	0.96	0.99	0.99	0.99	1.00	1.00	1.00	1.00	00.1	0.24	0.46	0.45	0.46	0.55	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.04	0.10	0.09	0.09	0.07	0.09	0.09	0.01	0.03	rs4906399	
	0.23	0.23	0.23	0.24	0.24	0.24	0.24	0.24).24	1.00	0.49	0.49	0.49	0.45	0.42	0.42	0.43	0.43	0.43	0.43	0.43	0.04	0.10	0.09	0.09	0.28	0.34	0.34	0.03	0.12	rs11160777	0.5
	0.45	0.45	0.45	0.45	0.46	0.45	0.46	0.46	0.46	0.49					0.74	0.74					0.75	80.0	0.18	0.19	0.19	0.14	0.18	0.18	0.05	0.17	rs7160557	-0.5
-	0.45	0.44	0.45	0.45	0.46	0.45	0.45	0.45).45	0.49						0.74	0.74	0.74	0.74	0.74	0.74	0.08	0.17	0.19	0.19	0.14	0.18	0.18	0.05	0.16	rs9671921	
	0.45	0.45	0.45	0.45	0.46	0.45	0.46	0.46).46	0.49					0.74	0.74					0.74	0.08	0.17	0.19	0.19	0.14	0.18	0.18	0.05	0.17	rs4900607	
	0.55	0.54	0.54	0.54	0.55	0.55	0.55	0.55	0.55	0.45											0.92	0.06	0.12	0.14	0.14	0.13	0.16	0.16	0.06	0.21	rs12100528	-1
	0.58	0.60	0.59	0.59	0.60	0.59	0.60	0.60	0.60	0.42	0.74		0.74								0.99	0.06	0.12	0.13	0.13	0.13	0.10	0.16	0.07	0.23	rc10132127	
	0.58	0.50	0.59	0.59	0.60	0.60	0.60	0.60	0.00	0.42	0.74	0.74	0.74								1.00	0.00	0.12	0.13	0.13	0.13	0.16	0.16	0.00	0.23	rs10135296	
	0.57	0.59	0.59	0.60	0.61	0.60	0.60	0.60	0.60	0.43		0.74									1.00	0.06	0.12	0.13	0.13	0.13	0.16	0.16	0.07	0.23	rs61319604	
	0.57	0.59	0.59	0.60	0.61	0.60	0.60	0.60	0.60	0.43		0.74									1.00	0.06	0.12	0.13	0.13	0.13	0.16	0.16	0.07	0.23	rs72714904	
	0.57	0.59	0.59	0.59	0.60	0.60	0.60	0.60	0.60	0.43		0.74									1.00	0.06	0.12	0.13	0.13	0.13	0.16	0.16	0.07	0.23	rs4906401	
	0.57	0.59	0.59	0.59	0.60	0.60	0.60	0.60	0.60	0.43		0.74	0.74								1.00	0.06	0.12	0.13	0.13	0.13	0.16	0.16	0.07	0.23	rs4906402	
	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.08	0.08	0.08	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06	1.00	0.39	0.41	0.41	0.02	0.01	0.01	0.00	0.01	rs1951585	
	0.09	0.09	0.09	0.09	0.10	0.10	0.10	0.10	0.10	0.10	0.18	0.17	0.17	0.12	0.12	0.12	0.12	0.12	0.12	0.12	0.12	0.39	1.00	0.95	0.95	0.03	0.03	0.03	0.00	0.01	rs11160776	
	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.19	0.19	0.19	0.14	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.41			1.00	0.03	0.03	0.03	0.00	0.02	rs10133836	
	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.19	0.19	0.19	0.14	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.41	0.95	1.00	1.00	0.03	0.03	0.03	0.00	0.02	rs2368994	
	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.28	0.14	0.14	0.14	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.02	0.03	0.03	0.03	1.00	0.72	0.72	0.01	0.04	rs7143936	
	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.34	0.18	0.18	0.18	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.01	0.03	0.03	0.03	0.72		1.00	0.01	0.04	rs11625697	
Ч	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.34	0.18	0.18	0.18	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.16	0.01	0.03	0.03	0.03	0.72	1.00	1.00	0.01	0.04	rs2005081	
L	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.03	0.05	0.05	0.05	0.06	0.07	0.06	0.07	0.07	0.07	0.07	0.07	0.00	0.00	0.00	0.00	0.01	0.01	0.01	1.00	0.32	rs145878302	
	0.04	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.12	0.17	0.16	0.17	0.21	0.23	0.23	0.23	0.23	0.23	0.23	0.23	0.01	0.01	0.02	0.02	0.04	0.04	0.04	0.32	1.00	rs137961671	
	's102	's727	s559	s283;	s145	's801	s121-	.s490	.s490	's111	's716	796s.	.s490	's121	s101;	s101;	s101;	s613	's727	's490	.s490	s195	s111	s101;	s236	·s714	s116;	.s200.	s145	's137		
	20464	12900	38939	91043	86787	0286	47936	6397	5399	6077	0557	1921	0607	00528	32127	32153	35296	19604	14904	6401	6402	1585	6077	33836	8994	3936	25697	5081	87830	9616		
	-	-	-		Ö					7													6						Ñ	7		

